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The adrenergic system plays a central role in stress signaling and stress is often
associated with increased production of ROS. However, ROS overproduction generates
oxidative stress, that occurs in response to several stressors. β-adrenergic signaling
is markedly attenuated in conditions such as heart failure, with downregulation and
desensitization of the receptors and their uncoupling from adenylyl cyclase. Transgenic
activation of β2-adrenoceptor leads to elevation of NADPH oxidase activity, with greater
ROS production and p38MAPK phosphorylation. Inhibition of NADPH oxidase or ROS
significantly reduced the p38MAPK signaling cascade. Chronic β2-adrenoceptor activation
is associated with greater cardiac dilatation and dysfunction, augmented pro-inflammatory
and profibrotic signaling, while antioxidant treatment protected hearts against these
abnormalities, indicating ROS production to be central to the detrimental signaling of
β2-adrenoceptors. It has been demonstrated that sirtuins are involved in modulating the
cellular stress response directly by deacetylation of some factors. Sirt1 increases cellular
stress resistance, by an increased insulin sensitivity, a decreased circulating free fatty
acids and insulin-like growth factor (IGF-1), an increased activity of AMPK, increased
activity of PGC-1a, and increased mitochondrial number. Sirt1 acts by involving signaling
molecules such P-I-3-kinase-Akt, MAPK and p38-MAPK-β. βAR stimulation antagonizes the
protective effect of the AKT pathway through inhibiting induction of Hif-1α and Sirt1 genes,
key elements in cell survival. More studies are needed to better clarify the involvement
of sirtuins in the β-adrenergic response and, overall, to better define the mechanisms by
which tools such as exercise training are able to counteract the oxidative stress, by both
activation of sirtuins and inhibition of GRK2 in many cardiovascular conditions and can be
used to prevent or treat diseases such as heart failure.
Keywords: oxidative stress, sirtuins, GRK2, β-adrenergic system, exercise training, heart failure, reactive oxygen
species
INTRODUCTION
The sympathetic adrenergic system plays a central role in stress
signaling and stress is often associated with increased production
of reactive oxygen species (ROS).
ROS production is the result of several mechanisms, including
generation during oxidative phosphorylation in themitochondria
as a product of normal cellular aerobic metabolism (Davies, 1995;
Ide et al., 1999). Thus, the major process from which the body
derives sufficient energy can also result in the production of ROS
(Ide et al., 1999). The balance between the production of ROS
and the activation of the antioxidant defense system is crucial
for the human physiology and the control of cellular homeosta-
sis. ROS play an important role in signaling processes, but their
overproduction generates oxidative stress. In fact, ROS can reg-
ulate cellular functions, e.g., during immune and inflammatory
processes (Remacle et al., 1995), in turn their overproduction
causes damage to cellular constituents, including DNA, proteins,
and lipids, especially when occurs with insufficient antioxidant
enzyme activity (Varma, 1991).
In several cellular signaling pathways (Nishida et al., 2000),
ROS act as second messengers downstream of specific ligands,
including Transforming Growth Factor-β1 (TGF-β1), Platelet-
Derived Growth Factor (PDGF), Fibroblast Growth Factor-2
(FGF-2), endothelin (Thannickal and Fanburg, 2000; Sawyer
et al., 2002; Griendling and FitzGerald, 2003; Machida et al.,
2003) and they are also involved in modulating the activity of spe-
cific transcription factors, such as Nuclear Factor-kB (NF-kB) and
Activator Protein–1 (AP-1) (Hsu et al., 2000; Hirotani et al., 2002;
Turpaev, 2002; Wu et al., 2002; Sabri et al., 2003; Rengo et al.,
2013a).
Elevated ROS have also been implicated in the development
and sustainment of several chronic degenerative diseases (i.e.,
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cancer, diabetes, neurodegenerative and cardiovascular condi-
tions) and in the mechanism of senescence and aging (Knight,
2000; Dröge, 2002; Westerheide et al., 2009; Marciano et al.,
2012; Paolillo et al., 2013; Rengo et al., 2013b), and it has been
suggested that they also contribute to adverse myocardial remod-
eling and the progression to heart failure (Sawyer et al., 2002;
Seddon et al., 2007). However, relatively little is known about
the type of ROS involved (e.g., superoxide, hydrogen peroxide,
peroxynitrite), their specific role in mediating myocyte hypertro-
phy, apoptosis, fibrosis that participate in myocardial remodeling
(Sawyer et al., 2002; Mann and Bristow, 2005; Seddon et al.,
2007), and in relationship to the overall progression tomyocardial
failure.
The sympathetic adrenergic system plays a central role in
ability to rapidly respond to various types of threats. One
important target of adrenergic stimulation is the heart, where
activation of β-adrenergic receptors causes increases in heart
rate (chronotropy), relaxation speed (lusitropy) and contractility
(inotropy) (Andersson et al., 2011).
Increased adrenergic drive is a major factor influencing the
development of pathological cardiac hypertrophy, a stage which
precedes overt heart failure. Whereas it is well known that
heart failure, a highly prevalent syndrome, is characterized by
both increased ROS production and β-adrenergic hyperactiv-
ity, still few evidence are available on the relationship between
β-adrenergic system and oxidative stress.
Recently it has been discovered that a family of enzymes
consists of NAD+-dependent histone/protein deacetylases, called
Sirtuins, represents pivotal regulator of redox cellular status.
In mammalian cells SIRT1 appears to control the cellular
response to stress by regulating the family of Forkhead tran-
scriptional factors (FOXOs) (Brunet et al., 2004) and directly
deacetylating the Heat Shock Factor (HSF1) and thus regulating
Heat Shock Proteins (HSPs) expression (Westerheide et al., 2009;
Corbi et al., 2012a).
This review is aimed to focus on the relationship between
adrenergic system activity and oxidative stress, with a light on
the possible implications of sirtuins in the regulation of this
mechanism.
OXIDATIVE STRESS IN THE CARDIOVASCULAR SYSTEM
Several in vitro and in vivo studies have demonstrated ROS activa-
tion in the cardiovascular system in response to various stressors
and in the failing heart (Ide et al., 1999; Cesselli et al., 2001;
Wallace, 2001; Sawyer et al., 2002; Sabri et al., 2003; Scortegagna
et al., 2003; Suematsu et al., 2003), and animal studies have also
suggested that antioxidants and ROS defense pathways can ame-
liorate ROS-mediated cardiac abnormalities (Chen et al., 1996;
Yen et al., 1996; Ho et al., 1998; Conrad et al., 2004; Giordano,
2005).
The ROS oxide (O2-), nitric oxide (NO), hydroxyl (OH-), and
peroxynitrite (ONOO-) are molecules characterized by the pres-
ence of unpaired electrons that are highly reactive with cysteine
residues in the catalytic center of cellular enzymes, thus making
them excellent signal transducers (Finkel, 1999).
ROS have been linked to key pathologic processes such as
cardiac hypertrophy (Nakamura et al., 1998) cardiomyocyte
apoptosis (von Harsdorf et al., 1999), ischemia-reperfusion
(Zweier et al., 1989) and heart failure itself (Ide et al., 1999). But
also oxidant overproduction occurs in response to several stres-
sors, including chemicals, drugs, pollutants, high-caloric diets,
and exercise (Kohen and Nyska, 2002). Physical exercise can
increase oxidative stress, eventually causing a perturbation of
homeostasis that is dependent on training specificity (Conti et al.,
2012a) and workload (Conti et al., 2013), but in turn it is also
able to counterbalance the deleterious effects of ROS by activation
of several antioxidant systems, such as Super Oxide Dismutases
(SODs), HSPs and catalase (Corbi et al., 2012a,b). The mecha-
nisms by which ROS mediate these different biologic responses
are not fully understood, but in many cases involve activation
of specific redox-sensitive signaling molecules. Three important
candidates for downstream effectors are p38 Mitogen-Activated
Protein Kinase (p38MAPK) and c-Jun Kinase (JNK), members of
the stress-activated kinase family, and the cell survival kinase Akt
(Griendling et al., 2000).
Angiotensin II, Tumor Necrosis Factor alpha (TNF-α) and
norepinephrine are neurohormones implicated in the develop-
ment of cardiac hypertrophy and progression to end-stage human
heart failure (Packer, 1998). There is currently evidence that
at least some hypertrophic effects induced by these agents are
mediated through ROS.
In vivo, under physiologic conditions, O2- is predominantly
inactivated by SODs, which are present in high concentrations
in mitochondria (MnSOD), cytosol (Cu/Zn SOD), or plasma
membrane/extracellular spaces, and consequently the formation
of ONOO- is minimal.
During physiological and pathological conditions, including
aging, SODs convert O2- to hydrogen peroxide (H2O2), which
has a longer half-life, can diffuse longer distances than O2-, and
is able to influence signaling events at more distant sites. In fact
H2O2 can regulate the activity of several enzymes essential for
Ca2+ release, growth, or apoptosis (phospholipases A2, C, and
D, Src kinase, p38MAPK, JNK and Akt/PKB) (Griendling et al.,
2000).
It has been demonstrated that the expression and activity of
the SOD system is modified in aging, with reduced cell abil-
ity to counteract the oxidant molecules, and consequent weak
resistance to ROS accumulation (Rinaldi et al., 2006). Obviously,
cytotypes with limited replication ability, such as brain and heart,
are particularly vulnerable to this phenomenon, suggesting that
it could explain, at least in part, high prevalence of cardiovascu-
lar and neurological disorders in elderly people (Navarro-Arévalo
et al., 1999). In fact, it is widely known that oxidative stress
and reduced antioxidant defense have negative effects on car-
diac structure and function (Singal et al., 1988) and they are also
involved in lipid membrane oxidation and other heart age-related
conditions (Corbi et al., 2012b).
HSPs are another system of cellular defense against oxida-
tive stress. These “stress-induced proteins” are ubiquitous and
highly conserved chaperones, important in the folding of new
synthesized or damaged proteins. Moreover, HSPs mediate mito-
chondrial protection against oxidative stress and some of those,
such as HSP70, have been associated with myocardial protec-
tion. Martin et al. (Martin et al., 1997) showed an increased
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survival in HSP70-transfected cardiomyocytes and consequent
increased expression of the HSP70 enzyme against ischemic car-
diac damage.
The metabolism of H2O2 is tightly regulated by the cellu-
lar glutathione peroxidases, which scavenge H2O2 (glutathione-
dependent) or catalase (glutathione-independent) (Sorescu and
Griendling, 2002). By converting H2O2 into water, catalase con-
stitutes a primary antioxidant defense system and could protect
cells from ROS and its deleterious consequences on diseases.
Recently it has been demonstrated that catalase protected
cardiac mitochondrial aconitase enzyme from oxidative damage
(Schriner et al., 2005) and overexpression of catalase targeted to
mitochondria protects mice from cardiac aging, providing direct
evidence for the role of mitochondrial ROS in the aging of this
vital organ (Dai et al., 2009).
In fact, accumulation of oxidative damage has also been con-
sidered responsible of many different aspects of the aged heart. It
has been found that cardiac fibrosis and size of myocytes increase
with aging, while the number of myocytes decreases and ventricu-
lar hypertrophy is almost a constant finding in the aging rat heart
(Anversa et al., 1986; Klima et al., 1990; Besse et al., 1994a). Hearts
of old rats are characterized by reduced antioxidant defenses, such
as SODs and Hsp 70 (Rinaldi et al., 2006).
Moreover, the oxidative stress with abnormalities inmitochon-
drial function, calcium (Ca2+) handling, electrolytes alterations,
hormones, and cardioprotective signaling have all been pro-
posed as potentially implicated in the aging process (Besse et al.,
1994b). In particular, regarding the effects of electrolytes changes
implicated in the regulation of myocardial function, it has been
demonstrated that magnesium (Mg2+) interferes on failed car-
diac contractility (Corbi et al., 2008) by modifying sarcoplasmic
reticular Ca2+ transport systems with a calcium antagonism
mechanism based on competition between Mg2+ and Ca2+ for
the same binding sites on key myocardial contractile proteins,
such as troponin C, myosin, and actin (Koss and Grubbs, 1994)
that could explain the opposite effects of Mg2+ and Ca2+ on
myocardial contractility (Kawano, 1998). Ca2+ overload can be
induced by direct effect of ROS on Ca2+ handling proteins or
indirectly, by inducing membrane lipid peroxidation (Valko et al.,
2007).
SIRTUINS AND OXIDATIVE STRESS IN THE
CARDIOVASCULAR SYSTEM
Another important mechanism involved in cellular redox reg-
ulation is represented by family of sirtuins, a cluster of seven
homologous proteins regulating cellular biology and metabolism
through deacetylation of histones and other cellular factors
such as NFkB, HSF1, p53, FOXOs, and Peroxisome Proliferator-
Activated Receptor Gamma Coactivator (PGC-1). By promoting
deacetylation, sirtuins can either promote or inhibit the activity
of several protein targets (Finkel et al., 2009; Haigis and Sinclair,
2010; Guarente, 2011).
SIRT1 and SIRT6 can deacetylate specific lysines on his-
tone tails to promote transcriptional silencing. SIRT1 also
deacetylates many non-histone proteins such as p53, FOXOs,
Nuclear Receptor Corepressor (SMRT/NCOR), and PGC-1alpha
(Finkel et al., 2009; Haigis and Sinclair, 2010; Guarente, 2011).
SIRT3 targets mitochondrial enzymes involved in metabolism,
ROS detoxification, and mitochondrial function including Long
Chain Acyl coe-enzyme A Dehydrogenase (LCAD), Isocitrate
Dehydrogenase 2 (IDH2), SOD2, and cyclophilin D (Hafner
et al., 2010; Zhong and Mostoslavsky, 2011). Other enzymatic
reactions catalyzed by selected sirtuins are the transfer of an
ADP-ribosyl group from NAD+ to an acceptor protein (SIRT1,
SIRT4, and SIRT6) (Finkel et al., 2009; Haigis and Sinclair, 2010;
Guarente, 2011), or the demalonylation and desuccinylation of
modified proteins (SIRT5) (Du et al., 2011). However, the biolog-
ical relevance of these reactions is only beginning to be unveiled
(Oellerich and Potente, 2012).
In particular, SIRT1, the human homologous of the family, is
involved in many functions of human physiology, including DNA
repair, cell cycle regulation, apoptosis, gene expression, and aging
(Grubisha et al., 2005). By FOXO3 acetylation and/or phospho-
rylation oxidative stress induces arrangement of SIRT1-FOXO3a,
complex indispensable for cell cycle arrest and induction of DNA
repair (Brunet et al., 2004). In turn, SIRT1 can modulate the
cellular stress response directly deacetylating some proteins and
regulating their expression (Porcu and Chiarugi, 2005). In fact,
SIRT1 modulates the threshold of cell death in the setting of
exogenous stress, including oxidative damage, interacting with
p53, inhibits Bax-induced apoptosis by deacetylation of Ku70,
and regulation of other targets linked to cell death (Cohen et al.,
2004) and cellular antioxidant activity (such as Mn-SOD and
catalase) (Corbi et al., 2012b).
Moreover, SIRT1 protects against endothelial dysfunction by
preventing stress-induced premature senescence, thereby modu-
lating the progression of cardiovascular diseases (Ota et al., 2007;
Li et al., 2011; Nadtochiy et al., 2011; Stein and Matter, 2011),
and it plays an essential role in mediating the survival of cardiac
myocytes under stress in vitro (Alcendor et al., 2004; Pillai et al.,
2005).
It has been observed that overexpression of Sirt1 reduces
expression of the Angiotensin II Type 1 Receptor (AT1R)
(Sunagawa, 2008) and this inhibition seems to prevent endothe-
lial dysfunction of cerebral arterioles (Arrick et al., 2008;Miyazaki
et al., 2008).
Although there are fewer studies of the other sirtuins, the
importance of SIRT3 for cardiac function has been demonstrated
by some authors. SIRT3 is expressed abundantly in the heart,
and has been reported to play a protective role against hyper-
trophy, acting at different levels. SIRT3 overexpression blocks
hypertrophy both in vitro and in vivo, whereas SIRT3−/− mice
exhibit enhanced susceptibility to hypertrophy (Sundaresan et al.,
2009), likely indirectly protecting against cardiac hypertrophy by
specifically control of ROS levels. Moreover, SIRT3 attenuates
Hypoxia-Inducible Factor 1-alpha (HIF-1α) activity indirectly by
controlling intracellular ROS (Finley et al., 2011), suggesting a
central regulatory function of sirtuins in the cellular response to
hypoxia (Oellerich and Potente, 2012).
More recently Cardus et al. demonstrated that the presence of
SIRT6 in endothelial cells protects from telomere and genomic
DNA damage, thus preventing a decrease in replicative capacity
and the onset of premature senescence. These findings suggest
that SIRT1 and SIRT6 collaborate at different levels to maintain
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endothelial homeostasis, with SIRT6 regulating chromatin func-
tions and DNA repair, and SIRT1 intracellular signaling networks
(Cardus et al., 2013).
Finally SIRT7 seems to be an essential regulator of tissue
homeostasis in the heart through its interaction with p53. Sirt7-
deficient primary cardiomyocytes show an approximately 200%
increase in basal apoptosis, and a significantly reduced resistance
to oxidative and genotoxic stress (Vakhrusheva et al., 2008; Corbi
et al., 2013).
Because the sirtuins activity depends on NAD+ availability it
has been suggested that their enzymatic activity is directly linked
to the energy and cellular redox status via the NAD+/NADH
ratio. Among the seven sirtuins, SIRT1 and SIRT3 are crucially
involved in regulation of cardiomyocyte energy metabolism, pro-
duction of ROS and signaling relevant to cell death/survival
(Tanno et al., 2012) playing different roles in regulation of
energy production and oxidative stress. Hearts consume large
amounts of O2 and yield high levels of ROS in the mitochon-
dria. In addition, various extracellular factors, such as angiotensin
II and Tumor Necrosis Factor-alpha (TNF-alpha), induce ROS
formation and promote cardiomyocyte death together with the
mitochondrial ROS (Giordano, 2005).
It has been demonstrated that MnSOD is required for normal
biological function of tissues. In fact, Li et al showed that Mn-
SOD−/− homozygous mutant mice die within the first 10 days
of life with a dilated cardiomyopathy, accumulation of lipid in
liver and skeletal muscle, and metabolic acidosis, and these find-
ings were related to a severe reduction in succinate dehydrogenase
(complex II) and aconitase (a TCA cycle enzyme) activities in the
heart (Li et al., 1995).
Furthermore, Loch et al found that MnSOD+/− mice dis-
played a decrease in fraction shortening and ejection fraction
and an increase in left ventricular internal diameter in systole,
and developed heart hypertrophy with accompanying fibrosis and
necrosis, demonstrating that lifelong reduction of MnSOD activ-
ity has a negative effect on normal heart function (Loch et al.,
2009).
Both SIRT1 and SIRT3 up-regulate Mn-SOD expression
through different mechanisms, such as HIF-2a (Dioum et al.,
2009) and/or FOXO4 (van der Horst et al., 2004) for SIRT1 and
FOXO3a for SIRT3 (Sundaresan et al., 2009). Sundaresan et al.
(2008) demonstrated that overexpression of both nuclear and
mitochondrial SIRT3 protected cardiomyocytes from genotoxic
stress and oxidant stress.
However, sirtuins adopt several other different tools to coun-
terbalance the oxidative stress.
For instance, Alcendor et al. showed that overexpression of
either Sirt1 or constitutively active FoxO1a in cultured car-
diac myocytes stimulated expression of catalase, suggesting that
FoxO1a plays an important role in mediating Sirt1-induced
upregulation of catalase, which may in part mediate suppression
of myocardial damage caused by oxidative stress (Alcendor et al.,
2007).
SIRT3 also increases activity of other ROS-detoxifying
enzymes indirectly. SIRT3 deacetylates and activates IDH2 and
glutamate dehydrogenase in murine liver (Alcendor et al., 2007;
Lombard et al., 2007), both of which produce NADPH in the
mitochondria. NADPH in turn is required for glutathione reduc-
tase to convert oxidized glutathione to reduced glutathione, which
is a crucial cofactor for mitochondrial glutathione peroxidase to
scavenge ROS.
Shinmura et al. (2011) demonstrated that treatment of car-
diomyocytes with resveratrol, an activator of SIRT1 and SIRT3,
decreased ROS production and improved cell survival after
hypoxia/reoxygenation without increasing the expression level of
MnSOD protein.
Recently, mitochondrial ALdehyde DeHydrogenase 2
(ALDH2) has been identified as a novel target of SIRT3 (Schlicker
et al., 2008; Lu et al., 2011). Excessive ROS in stressed hearts trig-
gers lipid peroxidation and accumulation of reactive aldehydes,
which in turn impairs mitochondrial function and induces cell
damage. ALDH2 removes the aldehydes reducing the toxicity
(Chen et al., 2010). Then, SIRT3-mediated ALDH2 activation
could be another mechanism that mitigates cardiomyocyte
damage induced by ROS, resulting in cardioprotection (Tanno
et al., 2012).
β ADRENERGIC SYSTEM AND OXIDATIVE STRESS IN
CARDIOVASCULAR SYSTEM
It is well established that β-adrenoceptor (βAR) activation stimu-
lates adenylyl cyclase activity through the participation of G pro-
teins and promotes the formation of cAMP in the myocardium
(Stiles et al., 1984; Bristow et al., 1990; Bohm, 1995; Chakraborti
et al., 2000). The elevated level of cAMP increases the intracel-
lular concentration of Ca2+ in cardiomyocytes on protein kinase
A (PKA) mediated phosphorylation of different Ca2+-handling
proteins in the membrane and produces the positive inotropic
effect in the heart (Stiles et al., 1984; Bristow et al., 1990; Bohm,
1995; Chakraborti et al., 2000). This βAR-mediated signal trans-
duction mechanism not only regulates the contractile activity of
the healthy heart, but it is also considered to provide critical
support for the maintenance of cardiac function during the devel-
opment of heart failure (Bristow et al., 1990; Bohm, 1995; Post
et al., 1999; Chakraborti et al., 2000; Sethi et al., 2007; Cannavo
et al., 2013a).
In failing hearts, elevated sympathetic activity initially com-
pensates for decreased cardiac contractility. βAR-mediated sig-
naling is markedly attenuated in heart failure subjects, owing to
the downregulation and desensitization of the receptors and their
uncoupling from adenylyl cyclase (Rockman et al., 2002; Di Lisa
et al., 2011; Rengo et al., 2012a; Femminella et al., 2013).
Many different mechanisms are implicated in the genesis of
heart failure. Effects of high levels of insulin on the cardiovascu-
lar function are well studied. In a model of isolated rats papillary
muscles, it was demonstrated that insulin-induced modulation
of contractility is calcium independent and that insulin leads to
a supersensitization on the β1-adrenoceptors (β1-AR) (Ferrara
et al., 2005). At the same time, elevated plasma free fat acid lev-
els have a stimulatory effect on sympathetic nervous system, as
showed by decreased QTc interval after weight loss (Corbi et al.,
2002; Bianco et al., 2013).
One of the pathophysiological mechanisms involved in the
genesis of heart failure is represented by a persistent β1-AR stim-
ulation, that evokes a multitude of cardiac toxic effects, including
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myocyte apoptosis and hypertrophy, as showed in vivo on rodent
hearts and in vitro on cultured cardiomyocytes (Ferrara et al.,
1997; Zheng et al., 2005; Cannavo et al., 2013b).
In particular it has been demonstrated a β1-AR downregula-
tion and desensitization due apparently to overt and sustained
stimulation, with largely unaltered β2-adrenoceptors (β2-AR)
(Molenaar et al., 2007; Feldman et al., 2008; Rengo et al., 2012b),
leading to an increased β2:β1 ratio.
β2-AR play an important role in the regulation of the angio-
genic response in HF, as showed by the evidence that β2-AR over-
expression was associated with a markedly increased capillary and
arteriolar length density and enhanced in vivo myocardial blood
flow and coronary reserve (Rengo et al., 2012b) and β-blockade
promotes cardiac angiogenesis in heart failure via activation of
VEGF signaling pathway (Rengo et al., 2013a).
G protein-coupled receptor kinases (GRKs) regulate numer-
ous G Protein-Coupled Receptors (GPCR) by phosphorylating
the intracellular domain of the active receptor, resulting in recep-
tor desensitization and internalization. GRKs also regulate GPCR
trafficking in a phosphorylation independent manner via direct
protein-protein interactions (Evron et al., 2012).
GPCR are seven-transmembrane receptors that transmit a
wide range of extracellular stimuli into cells, regulating themajor-
ity of biological processes. Upon agonist stimulation, GPCR
activate G proteins, which exchange bound GDP for GTP, lead-
ing to the dissociation of the G protein into activated Gα and
Gβγ subunits. This dissociation promotes downstream signaling
through specific effector proteins and second messengers (Pierce
et al., 2002; Takeda et al., 2002).
GRK2 is the most ubiquitous member of the GRK family.
GRK2 rapidly phosphorylate GPCR upon agonist stimulation and
facilitate the binding of arrestins to the phosphorylated receptors,
leading to uncoupling of the receptor from the G protein (Pitcher
et al., 1998a). This process, known as receptor desensitization, is
the loss of receptor responsiveness upon prolonged stimulation.
GPCR that are known substrates of GRK2 include the β2-AR, the
chemokine receptors CCR2b and CCR5, the Platelet Activating
Factor Receptor, and the neurokinin-1 receptor for substance P
(Pitcher et al., 1998a; Lombardi et al., 2002).
GRK2 binds PhosphoInositide 3-Kinase (PI3K) and recruits
it to the cell surface upon ligand stimulation of the βAR (Naga
Prasad et al., 2001). This interaction has been shown to be impor-
tant for βAR endocytosis, most likely via enhanced recruitment of
AP2 to the receptor (Naga Prasad et al., 2002; Salazar et al., 2013).
Blocking the interaction of GRK2with PI3K improves contrac-
tile function during heart failure by reversing βAR desensitization
abnormalities and restoring βAR signaling (Perrino et al., 2005;
Evron et al., 2012; Rengo et al., 2012c).
Interestingly, changes in GRK2 levels have been reported in a
number of disease states. In human GRK2 levels are increased in
myocardial tissue during heart failure (Ungerer et al., 1994; Rengo
et al., 2013a,b,c), myocardial infarction (Santulli et al., 2011) and
hypertension (Gros et al., 1997; Santulli et al., 2013).
Production of ROS has been detected in several cells stim-
ulated with cytokines, peptide growth factors, and agonists of
GPCRs (Thannickal and Fanburg, 2000). During inflammatory
processes, lymphocytes are exposed to H2O2 and other ROS that
are derived from activated macrophages and neutrophils as a first
line of defense against invading pathogens. Further downstream,
ROS regulate transcription factors, including NF-kB (Schreck
et al., 1991).
Some authors showed that exposure of lymphocytes to oxida-
tive stress results in a decrease in cellular GRK2 protein levels.
ROS produced by activated macrophages and neutrophils can
alter the activity of lymphocytes. Exposure of lymphocytes to
ROS results in increased intracellular calcium level, rapid tyrosine
phosphorylation of a variety of proteins (Schieven et al., 1993),
and activation of transcription factors such as NF-kB (Schreck
et al., 1991; Lombardi et al., 2002) (Figure 1).
Oxidative stress activates several other kinase signaling path-
ways, such as Protein Kinase C (PKC), MAPK, and PI3K.
Activated PKC can phosphorylate GRK2, with increased kinase
activity (Chuang et al., 1995). Interestingly, inhibition of PKC
does not affect basal GRK2 levels nor does it interfere with the
H2O2-induced decrease in cellular GRK2. In addition, specific
inhibitors of MAPK or PI3K do not have any effect on H2O2-
induced decreases in GRK2 protein (Lombardi et al., 2002).
Previous reports showed that GRK2 is the predominant GPCR
kinase involved in agonist-induced receptor sequestration of the
β2-AR. Moreover, studies in transfected cell systems suggest that
changes in the intracellular level of GRK2 alter the rate and extent
of sequestration of the β2-AR (Ferguson et al., 1996; Penela et al.,
1998; Lombardi et al., 2002).
A growing body of evidence has shown that GRK2 is capa-
ble of phosphorylating non-receptor substrates. GRK2 is a
microtubule-associated kinase that directly phosphorylates tubu-
lin following βAR stimulation (Pitcher et al., 1998b; Yoshida
et al., 2003), suggesting a functional link between GRK2 and the
cytoskeleton. Accordingly, GRK2 levels can affect agonist-induced
βAR internalization in amechanism involvingmicrotubule stabil-
ity (Vroon et al., 2007). GRK2-mediated phosphorylation of the
membrane-cytoskeleton linkers, radixin (Kahsai et al., 2010) and
ezrin (Cant and Pitcher, 2005), provides another indication for
this functional link to the cytoskeleton.
Another important target of GRK2 kinase activity is the Insulin
Receptor Substrate 1 (IRIS).
It has been reported that increased GRK2 levels mediate
insulin resistance in myoblasts and adipocytes via a mecha-
nism which involves sequestration of Gαq and IRIS (Usui et al.,
2005; Garcia-Guerra et al., 2010). Interestingly, GRK2 directly
phosphorylates IRIS in cardiomyocytes, a process that negatively
affects cardiac glucose uptake and insulin sensitivity following
ischemic injury and ultimately leads to the development of heart
failure (Ciccarelli et al., 2011; Evron et al., 2012).
In fact, GRK2, also known as βAR kinase 1 (βARK1), provides
a link between altered vascular/tissue physiology in insulin resis-
tance and impaired IRIS signaling. GRK2 can interfere directly
with Gαq/11-mediated signaling via its regulator of G protein
signaling domain/GAP activity (Usui et al., 2004). Increased
plasma concentration of the vasoconstrictive ET-1 polypeptide
is associated with insulin resistance and/or hypertension (Kohno
et al., 1990), which is, in turn, promoted by direct and indirect
(sympathoadrenal and angiotensin II dependent) effects of com-
pensatory hyperinsulinaemia to cause sodium retention (Yatabe
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FIGURE 1 | Cellular response to oxidative stress mediating by
β-adrenergic response and sirtuins involvement. The ROS induce GRK2
hyperactivity that determines desensitization and internalization of βARs with
induction of cardiac hypertrophy (via AKT/NFkB pathway), apoptosis and
senescence (by inhibition of FOXOs). Sirtuins (and their activators) are able to
counteract these actions by direct effects on different molecules. ROS,
reactive oxygen species; CR, caloric restriction; Ac, acetyl; P, phosphoryl. ↓
activation; ⊥ inhibition.
et al., 2010). The correlation between excessive β-adrenergic activ-
ity and insulin resistance has long been noted (Deibert and
DeFronzo, 1980). While tissue GRK2 levels have been correlated
with plasma norepinephrine/epinephrine levels (Cho et al., 1999),
GRK2 can be upregulated in cultured cells by chronic insulin
(Garcia-Guerra et al., 2010), potentially as a result of PI3K-
dependent stabilization of GRK2 (Salcedo et al., 2006). Thus,
both local/circulating GPCR ligands associated with insulin resis-
tance/hyperinsulinaemia, and insulin itself, contribute to the high
GRK2 levels observed in insulin-resistant rodent/human tissues
(Garcia-Guerra et al., 2010; Copps and White, 2012).
These findings demonstrate that lowering GRK2 in myocytes
after ischemic injury will contribute to restore cardiacmetabolism
and prevent the development of subsequent heart failure (Evron
et al., 2012).
Moreover, during heart failure GRK2 is up-regulated in the
adrenal medulla, causing α2-adrenoceptor dysfunction and cat-
echolamine hypersecretion. By decreasing GRK2 levels in the
adrenal gland, β-blocker treatment appears to restore adrenal
α2-AR density and signaling at the plasma membrane and cat-
echolamine feedback inhibition, reducing sympathetic overdrive
in chronic heart failure (Rengo et al., 2012c).
Thus, the favorable effects of GRK2 inhibition in cardiac dis-
ease can be ascribed not only to the direct improvement of
adrenergic response but also tomore complex interactions among
different and specific systems involved in the pathophysiological
response to myocardial injury (Rengo et al., 2012a).
Also it is well known that oxidative stress represents an under-
lying mechanism involved in insulin resistance development. The
evidence that reactive nitrogen and oxygen species generation
occurs when endothelial cells respond to high glucose (Garcia
Soriano et al., 2001) suggests another link between oxidative stress
and β-adrenergic activity in the involvement of many cardiovas-
cular conditions.
ROS may change the functioning of GPCRs during disease
processes via the calpain-dependent regulation of cellular GRK2
levels (Lombardi et al., 2002).
Moreover, in vitro studies have revealed several non-classical
signaling molecules utilized by β2-AR, including β-arrestin 1
(Drake et al., 2008; Gong et al., 2008; Tilley et al., 2009),
p38MAPK (Gong et al., 2008; McAlees and Sanders, 2009) and
ROS (Yin et al., 2006; Gong et al., 2008). Transgenic activation
of β2-AR in cardiomyocytes leads to a sustained elevation of
NADPH oxidase activity, which is accompanied by a greater ROS
production as well as phosphorylation of p38MAPK. Inhibition
of NADPH oxidase or ROS significantly reduced the p38MAPK
signaling cascade. Chronic β2-AR activation in vivo is associated
with greater extent of cardiac dilatation and dysfunction as well
as augmented pro-inflammatory and profibrotic signaling, while
antioxidant treatment protected hearts against these abnormali-
ties, indicating ROS production to be central to the detrimental
signaling of β2-AR. These findings highlight that the coupling of
β2-AR with NADPH oxidase derived ROS/p38 MAPK is pivotal
to the adverse signaling mechanism, and thus forms a potential
therapeutic target (Xu et al., 2011).
More recently Chen et al. (2013) have been demonstrated that
GRK2 localizes to heart mitochondria and it was an absolute
requirement for prodeath signaling after oxidative and ischemic
stress. Specifically, mitochondrial targeting of GRK2 in myocytes
after ischemic injury promotes prodeath signaling because
mitochondrial accumulation of GRK2 in myocytes increases
after oxidative stress and it is dependent on ERK-mediated
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phosphorylation of GRK2, with subsequent movement to mito-
chondria dependent on binding of phosphorylated GRK2 to
Hsp90. Then the authors suggested that blocking this mechanism
led to cardioprotection.
β-ADRENERGIC SYSTEM, OXIDATIVE STRESS AND
SIRTUINS
It has been demonstrated that sirtuins, NAD+/NADH deacety-
lases, are involved in modulating the cellular stress response
directly by deacetylation of some factors that are also implicated
in endothelial function control (Tang et al., 2012; Conti et al.,
2013).
Sirt1 extends the lifespan of many organisms by increasing
cellular stress resistance (Brunet et al., 2004; Alcendor et al.,
2007), by an increase insulin sensitivity, a decrease circulat-
ing free fatty acids and insulin-like growth factor (IGF-1), an
increased activity of the energy-sensing enzyme, AMP-activated
Protein Kinase (AMPK), increased activity of Peroxisome pro-
liferator activated receptor-gamma coactivator-alpha (PGC-1a),
and increased mitochondrial number (Opie and Lecour, 2007).
The requirement of NAD+ for Sirt1 activity implies that
Sirt1 effectiveness depends on the cellular metabolic state
(Conti et al., 2012a). Moreover, Sirt1 acts by involving sig-
naling molecules such phosphatidyl-inositol-3-phosphate-kinase
(PI3K)-Akt, MAPK (Bezstarosti et al., 2006) and p38-MAPK-β
(Das et al., 2006) (Figure 1).
SIRT1 has been demonstrated to be localized predominantly in
the nucleus or cytoplasm depending on the cell type. SIRT1 shut-
tles between the two cellular compartments in response to cellular
stress in C2C12 cells and cardiomyocytes (Tanno et al., 2010), and
during differentiation in neural precursor cells (Hisahara et al.,
2008).
The nucleo-cytoplasmic shuttling is regulated by nuclear local-
ization signals and nuclear export signals in the aminoacid
sequences of SIRT1. PI3K/Akt- and JNK1- mediated phosphory-
lation of SIRT1 induces its nuclear translocation (Tanno et al.,
2007; Nasrin et al., 2009). Nuclear localization of SIRT1 seems to
be necessary for its protective function in cardiomyocytes (Tanno
et al., 2007, 2010) whereas the biological significance of cytoplas-
mic SIRT1 remains to be determined. It has been demonstrated
that resveratrol, a SIRT1 activator, improves insulin sensitivity in
diet-induced obesity in mice (Baur et al., 2006; Lagouge et al.,
2006). Sun et al. (2007) found that SIRT1 repressed protein phos-
phatase 1B (PTP1B) and thereby increased the level of insulin
receptor phosphorylation, improving insulin sensitivity both in
C2C12 myotubes and in high fat-fed mice.
Recently it has been demonstrated that βAR stimulation antag-
onizes the protective effect of the Akt pathway that is mediated
by both insulin and hypoxia preconditioning, through inhibiting
their induction of Hif-1α and Sirt1 gene, which are key elements
in cell survival (Rane et al., 2010).
Akt overexpression in mice suppressed autophagy, which
was associated with cardiac hypertrophy, interstitial fibrosis
and contractile dysfunction (Hua et al., 2011). SIRT1 regulates
autophagy by interacting with and deacetylating autophagy-
related proteins Atg5, Atg7, and Atg8 (Lee et al., 2008). Recently,
Hariharan et al. (2010) demonstrated that SIRT1 was required
for starvation-induced autophagy in cardiomyocytes, in which
SIRT1-mediated deacetylation of FOXO1 and subsequent activa-
tion of Rab7 plays a role.
Furthermore, FOXO1 was indispensable for maintenance of
cardiac function after starvation, suggesting that autophagy
induced by activation of the SIRT1-FOXO1 axis is an impor-
tant adaptive mechanism in the failing heart (Tanno et al.,
2012). Moreover, recently it has been demonstrated that reduced
SERCA2a protein level, ventricular dysfunction, ventricular
dilatation and mortality in a mouse model of type-1 diabetes
were nearly normalized by treatment with resveratrol in a SIRT1-
dependent manner (Sulaiman et al., 2010; Tanno et al., 2012).
The presence of high levels of norepinephrine has been consid-
ered as a pathological marker of heart failure (Tavares et al., 2008).
Another demonstration of the relationship between adrenergic
system and sirtuins is represented by the evidence that resvera-
trol prevents norepinephrine induced hypertrophy in adult rat
cardiomyocytes, by activating NO-AMPK pathway (Thandapilly
et al., 2011). Thandapilly et al. (2011) proposed that nore-
pinephrine binds with the β-adrenergic receptor on the cardiac
cell membrane, the sarcolemma, and activates phospholipase C
resulting in the formation of 1,2-diacylglycerol (DAG) and inosi-
tol triphosphate (IP3). In turn, DAG stimulates cytosolic protein
kinase activity resulting in increased protein synthesis leading
to the development of cardiac hypertrophy (Eskildsen-Helmond
et al., 1997).
In addition, resveratrol restored sirtuin activity, and thereby
improve cardiac function in rats with diabetic cardiomyopathy
(Sulaiman et al., 2010). Breen et al. (2008) studied the interac-
tion between AMPK and sirtuin in resveratrol mediated signaling
in skeletal muscle cells. In this study increased skeletal muscle glu-
cose uptake was observed upon resveratrol treatment which was
mediated by the sirtuin-AMPK dependent pathway (Breen et al.,
2008). Moreover, it has been also demonstrated that resveratrol
prevented cardiomyocyte hypertrophy by restoring the impaired
AMPK activity in phenylephrine exposed cardiomyocytes as well
as in SHR rats (Chan et al., 2008; Dolinsky et al., 2009) suggesting
an important role for AMPK in mediating resveratrol effects.
Some authors (Dolinsky et al., 2009; Thandapilly et al., 2010)
have recently reported that resveratrol prevented the development
of pathological cardiac hypertrophy in genetically hypertensive
rats without any effect on blood pressure, which is consid-
ered a pathological stimulus for the development of hypertrophy
(Thandapilly et al., 2010, 2011).
The antioxidant activities of sirtuins are well known. SIRT3
blocks the cardiac hypertrophic response through activation of
Foxo-dependent antioxidants, MnSOD and catalase, as well as
suppressing ROS-mediated Ras activation and the downstream
MAPK/ERK and PI3K/Akt signaling pathways (Sundaresan et al.,
2009) (Figure 1). In particular, SIRT1 and SIRT3 appear to share
similar ROS-accumulating end-point targets that cause cardiac
hypertrophy. All of these findings support the hypothesis that
use and development of sirtuin-specific activators and inhibitors
may help further dissect the collaborative functions of SIRT1 and
SIRT3 in the heart.
Less is known about the physiological role of SIRT7 in the
heart. SIRT7 is a nuclear protein that associates with rDNA and
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interacts with RNA (Ford et al., 2006). It is not clear whether
SIRT7 exhibits NAD+-dependent deacetylase activity, but reports
suggest that it does respond to metabolic conditions by stimu-
lating ribosomal biogenesis in dividing cells (Michishita et al.,
2005) and it regulates heart cell death and damage by inhibit-
ing p53, Ras, and Akt signaling pathways (Vakhrusheva et al.,
2008). In fact, SIRT7-deficient mice develop heart hypertrophy
and inflammatory cardiomyopathy, which is characterized by
extensive fibrosis (Vakhrusheva et al., 2008). However, the molec-
ular details explaining how SIRT7 targets these pathways remains
unclear (Schug and Li, 2010).
Recently it has been proposed that β-adrenergic activation
of the cAMP/PKA pathway rapidly increases SIRT1 activity in a
NAD+ independent fashion. This mechanism enables SIRT1 to
respond swiftly to the changing metabolic needs of the organ-
ism in settings of environmental stress. Cantó and Auwerx
suggested that SIRT1 acts as a metabolic effector, synchroniz-
ing metabolic pathways with nutrient availability (Cantó and
Auwerx, 2012). The molecular mechanism by which NAD+ reg-
ulates SIRT1 catalytic activity, however, is still not fully under-
stood. In a low energy state, SIRT1 deacetylates and increases
the activity of PGC-1a, leading to transcriptional upregulation
of genes involved in lipid catabolism and mitochondrial bio-
genesis (Rodgers et al., 2005; Lagouge et al., 2006; Gerhart-
Hines et al., 2007). Current understanding of the regulation
of this process has emphasized a role for AMPK signaling in
controlling the abundance of the SIRT1 substrate NAD+. The
elevated AMP/ATP ratio during energy deficiency triggers phos-
phorylation of PGC-1a by AMPK, which primes PGC-1a for
SIRT1-dependent deacetylation (and activation) (Cantó et al.,
2009).
AMPK also increases the concentration of intracellular NAD+,
further fueling SIRT1 deacetylase activity. However, both of these
processes occur over the course of several hours, too long to
permit rapid response to acute changes in energy stress.
SIRT1 activity has been reported previously to be regulated
by post-translational modifications, such as phosphorylation by
JNK. But the fact that the residues targeted by this pathway do
not reside in the catalytic domain and are not conserved evolu-
tionarily indicates this is an unlikely mechanism to regulate the
well-conservedmetabolic functions of SIRT1 (Cantó and Auwerx,
2012). Given the evidence supporting a function for SIRT1 in
bioenergetics stress, Gerhart-Hines et al. (2011) hypothesized
that stress-induced β-adrenergic signaling might regulate SIRT1
activity. Activation of the βAR increases intracellular cAMP con-
centration and activates PKA and its downstream effectors. The
authors demonstrated that each component of the βAR-cAMP-
PKA axis is essential to SIRT1 deacetylation of PGC-1a. In U2OS
cells, treatment with β-adrenergic agonists (epinephrine and clen-
buterol) or cAMP mimetics (forskolin and 8-BrcAMP) led to
potent dose-dependent deacetylation of PGC-1a within 30min.
Forskolin-induced PGC-1a deacetylation was dependent on both
PKA and SIRT1, but this effect was abolished by genetic deletion
of SIRT1 in mouse embryonic fibroblasts. Furthermore, reduc-
tion of SIRT1 expression prevented forskolin-mediated upregula-
tion of the PGC-1a target genes ERRa and PDK4 (Gerhart-Hines
et al., 2011).
The rapidity with which SIRT1 transduced cAMP/PKA sig-
nals suggested that SIRT1 might be a direct target for PKA
phosphorylation. Using mass spectrometry, the authors iden-
tified a residue on SIRT1 in the catalytic domain that was
uniquely phosphorylated in response to forskolin treatment. They
showed that Serine 434 (S434) phosphorylation was dependent
on cAMP/PKA signaling and was rapidly reversed by removal
of cAMP mimetic (forskolin). Furthermore, the authors showed
that S434 phosphorylation was essential for the forskolin-induced
increase in intrinsic SIRT1 enzymatic activity (Gerhart-Hines
et al., 2011). Importantly, in all experiments, total NAD+ content
was unchanged by cAMP/PKA signaling, indicating that cAMP-
mediated deacetylation of PGC-1a was independent of NAD+
regulation of SIRT1. Gerhart-Hines et al. depicts SIRT1 as a
dynamic orchestrator of both acute stress (βAR/cAMP signaling)
and sustained energy crisis (AMPK-mediated changes in PGC-
1a phosphorylation and NAD+ concentration) (Gerhart-Hines
et al., 2007, 2011; Chao and Tontonoz, 2012).
CONCLUSIONS
Oxidative stress represents the primum movens of several chronic
degenerative diseases, especially of the cardiovascular system
(Ferrara et al., 2006; Conti et al., 2012b). In the last decades
several studies have demonstrated as the β-adrenergic system
represents the target of the oxidative damage and, in turn, the
responsible of oxidants production. The sirtuins, a new class of
histone-deacetylases, seem to be the best defense of the cell to
counterbalance the oxidative stress through the action on differ-
ent pathways. Most part of the research on these molecules in
the last years has been focused on the sirtuins activators, show-
ing as the caloric restriction, the resveratrol and in particular the
exercise training are able to mediate their beneficial effects by
induction of sirtuins activity.
More recently, the use of a SIRT1 activator SRT2104 on
cardiovascular function provided positive effects on lipid pro-
files, but were unable to demonstrate beneficial effects on vas-
cular, endothelial, or platelet function compared with placebo
(Venkatasubramanian et al., 2013).
Therefore, as suggested by Merksamer et al. (2013), for the
future it will be important to develop experimental models in
which the levels of oxidative stress and the activities of sirtuins can
be precisely modulated to determine if sirtuins have a causative
role in lifespan extension.
Moreover, as discussed above and showed in Figure 1, whereas
the mechanisms involved in the cellular response to oxidative
stress are represented by the same actors, very few studies have
been performed to link the β-adrenergic system and sirtuins
activity, and most of them are only focused on the metabolic
pathway.
Therefore, more studies are needed to better clarify the
involvement of sirtuins in the β-adrenergic response and, overall,
to better define the mechanisms by which tools such as exercise
training are able to counteract the oxidative stress, by both acti-
vation of sirtuins (Ferrara et al., 2008) and inhibition of GRK2
(Rengo et al., 2010) in many cardiovascular conditions.
The activation or overexpression of sirtuins leads to measur-
able increases in health and resistance to different stress, making
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them an appealing target for the development of interventions
to promote improvements in health. However, more research is
needed before we can effectively target sirtuins for therapeutic
purposes. So, currently, although sirtuins represent promising
therapeutic targets, their role in the regulation of mammalian
lifespan remains an open question (Accili et al., 2011). Then, the
future perspective could be represented by studies performed to
identify the efficacy of sirtuin activators in the prevention and/or
treatment of cardiovascular diseases such as heart failure.
REFERENCES
Accili, D., de Cabo, R., and Sinclair, D. A. (2011). An unSIRTain role in longevity.
Nat. Med. 17, 1350–1351. doi: 10.1038/nm1111-1350
Alcendor, R. R., Gao, S., Zhai, P., Zablocki, D., Holle, E., Yu, X., et al. (2007). Sirt1
regulates aging and resistance to oxidative stress in the heart. Circ. Res. 100,
1512–1521. doi: 10.1161/01.RES.0000267723.65696.4a
Alcendor, R. R., Kirshenbaum, L. A., Imai, S., Vatner, S. F., and Sadoshima, J.
(2004). Silent information regulator 2alpha, a longevity factor and class III
histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac
myocytes. Circ. Res. 95, 971–980. doi: 10.1161/01.RES.0000147557.75257.ff
Andersson, D. C., Fauconnier, J., Yamada, T., Lacampagne, A., Zhang, S. J., Katz,
A., et al. (2011). Mitochondrial production of reactive oxygen species con-
tributes to the β-adrenergic stimulation of mouse cardiomycytes. J. Physiol. 589,
1791–1801. doi: 10.1113/jphysiol.2010.202838
Anversa, P., Hiler, B., Ricci, R., Guideri, G., and Olivetti, G. (1986). Myocyte cell
loss and myocyte hypertrophy in the aging rat heart. J. Am. Coll. Cardiol. 8,
1441–1448. doi: 10.1016/S0735-1097(86)80321-7
Arrick, D. M., Sharpe, G. M., Sun, H., and Mayhan, W. G. (2008). Losartan
improves impaired nitric oxide synthase-dependent dilatation of cere-
bral arterioles in type 1 diabetic rats. Brain Res. 1209, 128–135. doi:
10.1016/j.brainres.2008.03.020
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., et al.
(2006). Resveratrol improves health and survival of mice on a high-calorie diet.
Nature 444, 337–342. doi: 10.1038/nature05354
Besse, S., Robert, V., Assayag, P., Delcayre, C., and Swynghedauw, B. (1994a).
Nonsynchronous changes in myocardial collagen mRNA and protein during
aging: effect of DOCA-salt hypertension. Am. J. Physiol. 267, H2237–H2244.
Besse, S., Delcayre, C., Chevalier, B., Hardouin, S., Heymes, C., Bourgeois, F., et al.
(1994b). Is the senescent heart overloaded and already failing?Cardiovasc. Drugs
Ther. 8, 581–587. doi: 10.1007/BF00877412
Bezstarosti, K., Das, S., Lamers, J. M., and Das, D. K. (2006). Differential pro-
teomic profiling to study the mechanism of cardiac pharmacological precon-
ditioning by resveratrol. J. Cell. Mol. Med. 10, 896–907. doi: 10.1111/j.1582-
4934.2006.tb00533.x
Bianco, A., Mazzarella, G., Turchiarelli, V., Nigro, E., Corbi, G., Scudiero, O.,
et al. (2013). Adiponectin: an attractive marker for metabolic disorders in
Chronic Obstructive Pulmonary Disease (COPD). Nutrients 5, 4115–4125. doi:
10.3390/nu5104115
Bohm, M. (1995). Alterations of beta-adrenoceptor-G-protein-regulated
adenylyl cyclase in heart failure. Mol. Cell Biochem. 147, 147–160. doi:
10.1007/BF00944795
Breen, D. M., Sanli, T., Giacca, A., and Tsiani, E. (2008). Stimulation of muscle cell
glucose uptake by resveratrol through sirtuins and AMPK. Biochem. Biophys.
Res. Commun. 374, 117–122. doi: 10.1016/j.bbrc.2008.06.104
Bristow, M. R., Hershberger, R. E., Port, J. D., Gilbert, E. M., Sandoval, A.,
Rasmussen, R., et al. (1990). Beta-adrenergic pathways in nonfailing and failing
human ventricular myocardium. Circulation 82, I12–I25.
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., et al.
(2004). Stress-dependent regulation of FOXO transcription factors by the SIRT1
deacetylase. Science 303, 2011–2015. doi: 10.1126/science.1094637
Cannavo, A., Rengo, G., Liccardo, D., Pagano, G., Zincarelli, C., De Angelis, M. C.,
et al. (2013a). β1-Adrenergic receptor and Sphingosine-1-Phosphate Receptor
1 reciprocal down-regulation influences cardiac hypertrophic response and
progression toward heart failure: protective role of S1PR1 cardiac gene
therapy. Circulation 128, 1612–1622. doi: 10.1161/CIRCULATIONAHA.113.
002659
Cannavo, A., Rengo, G., Liccardo, D., Pironti, G., Scimia, M. C., Scudiero, L.,
et al. (2013b). Prothymosin alpha protects cardiomyocytes against ischemia-
induced apoptosis via preservation of Akt activation. Apoptosis 18, 1252–1261.
doi: 10.1007/s10495-013-0876-9
Cant, S. H., and Pitcher, J. A. (2005). G protein-coupled receptor kinase 2-mediated
phosphorylation of ezrin is required for G protein-coupled receptor-dependent
reorganization of the actin cytoskeleton. Mol. Biol. Cell 16, 3088–3099. doi:
10.1091/mbc.E04-10-0877
Cantó, C., and Auwerx, J. (2012). Targeting sirtuin 1 to improve metabolism: all
you need is NAD(+)? Pharmacol. Rev. 64, 166–187. doi: 10.1124/pr.110.003905
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J.
C., et al. (2009). AMPK regulates energy expenditure by modulating NAD+
metabolism and SIRT1 activity. Nature 458, 1056–1060. doi: 10.1038/nature
07813
Cardus, A., Uryga, A. K., Walters, G., and Erusalimsky, J. D. (2013). SIRT6 pro-
tects human endothelial cells from DNA damage, telomere dysfunction, and
senescence. Cardiovasc. Res. 97, 571–579. doi: 10.1093/cvr/cvs352
Cesselli, D., Jakoniuk, I., Barlucchi, L., Beltrami, A. P., Hintze, T. H., Nadal-Ginard,
B., et al. (2001). Oxidative stress-mediated cardiac cell death is a major determi-
nant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ.
Res. 89, 279–286. doi: 10.1161/hh1501.094115
Chakraborti, S., Chakraborti, T., and Shaw, G. (2000). Beta-adrenergic mechanisms
in cardiac diseases: a perspective. Cell Signal. 12, 499–513. doi: 10.1016/S0898-
6568(00)00087-5
Chan, A. Y., Dolinsky, V. W., Soltys, C. L., Viollet, B., Baksh, S., Light, P. E., et al.
(2008). Resveratrol inhibits cardiac hypertrophy via AMP-activated protein
kinase and Akt. J. Biol. Chem. 283, 24194–24201. doi: 10.1074/jbc.M802869200
Chao, L. C., and Tontonoz, P. (2012). SIRT1 regulation-it ain’t all NAD. Mol. Cell.
45, 9–11. doi: 10.1016/j.molcel.2011.12.017
Chen, C. H., Sun, L., and Mochly-Rosen, D. (2010). Mitochondrial alde-
hyde dehydrogenase and cardiac diseases. Cardiovasc. Res. 88, 51–57. doi:
10.1093/cvr/cvq192
Chen, E. P., Bittner, H. B., Davis, R. D., Folz, R. J., and Van Trigt, P.
(1996). Extracellular superoxide dismutase transgene overexpression preserves
postischemic myocardial function in isolated murine hearts. Circulation 94,
II412–II417.
Chen, M., Sato, P. Y., Chuprun, J. K., Peroutka, R. J., Otis, N. J., Ibetti,
J., et al. (2013). Prodeath signaling of G protein-coupled receptor kinase
2 in cardiac myocytes after ischemic stress occurs via extracellular signal-
regulated kinase-dependent heat shock protein 90-mediated mitochon-
drial targeting. Circ. Res. 112, 1121–1134. doi: 10.1161/CIRCRESAHA.112.
300754
Cho, M. C., Rao, M., Koch, W. J., Thomas, S. A., Palmiter, R. D., and Rockman,
H. A. (1999). Enhanced contractility and decreased beta-adrenergic recep-
tor kinase-1 in mice lacking endogenous norepinephrine and epinephrine.
Circulation 99, 2702–2707. doi: 10.1161/01.CIR.99.20.2702
Chuang, T. T., LeVine, H. 3rd., and De Blasi, A. (1995). Phosphorylation and acti-
vation of beta-adrenergic receptor kinase by protein kinase C. J. Biol. Chem. 270,
18660–18665. doi: 10.1074/jbc.270.31.18660
Ciccarelli, M., Chuprun, J. K., Rengo, G., Gao, E., Wei, Z., Peroutka, R. J., et al.
(2011). G protein-coupled receptor kinase 2 activity impairs cardiac glucose
uptake and promotes insulin resistance after myocardial ischemia. Circulation
123, 1953–1962. doi: 10.1161/CIRCULATIONAHA.110.988642
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., et al.
(2004). Calorie restriction promotes mammalian cell survival by inducing the
SIRT1 deacetylase. Science 305, 390–392. doi: 10.1126/science.1099196
Conrad, M., Jakupoglu, C., Moreno, S. G., Lippl, S., Banjac, A., Schneider, M., et al.
(2004). Essential role formitochondrial thioredoxin reductase in hematopoiesis,
heart development, and heart function. Mol. Cell. Biol. 24, 9414–9423. doi:
10.1128/MCB.24.21.9414-9423.2004
Conti, V., Corbi, G., Russomanno, G., Simeon, V., Ferrara, N., Filippelli, W., et al.
(2012a). Oxidative stress effects on endothelial cells treated with different ath-
letes’ sera. Med. Sci. Sports Exerc. 44, 39–49. doi: 10.1249/MSS.0b013e31822
7f69c
Conti, V., Russomanno, G., Corbi, G., and Filippelli, A. (2012b). Exercise train-
ing in aging and diseases. Transl. Med. UniSa. 3, 74–80. Available online at:
http://hdl.handle.net/10556/629
Conti, V., Russomanno, G., Corbi, G., Guerra, G., Grasso, C., Filippelli, W.,
et al. (2013). Aerobic training workload affects human endothelial cells
www.frontiersin.org November 2013 | Volume 4 | Article 324 | 9
Corbi et al. Sirtuins, oxidative stress and beta-adrenergic system
redox homeostasis. Med. Sci. Sports Exerc. 45, 644–653. doi: 10.1249/MSS.
0b013e318279fb59
Copps, K. D., and White, M. F. (2012). Regulation of insulin sensitivity by ser-
ine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and
IRS2. Diabetologia 55, 2565–2582. doi: 10.1007/s00125-012-2644-8
Corbi, G. M., Carbone, S., Ziccardi, P., Giugliano, G., Marfella, R., Nappo, F., et al.
(2002). FFAs and QT intervals in obese women with visceral adiposity: effects
of sustained weight loss over 1 year. J. Clin. Endocrinol. Metab. 87, 2080–2083.
doi: 10.1210/jc.87.5.2080
Corbi, G., Acanfora, D., Iannuzzi, G. L., Longobardi, G., Cacciatore, F., Furgi, G.,
et al. (2008). Hypermagnesemia predicts mortality in elderly with congestive
heart disease: relationship with laxative and antacid use. Rejuvenation Res. 11,
129–138. doi: 10.1089/rej.2007.0583
Corbi, G., Bianco, A., Turchiarelli, V., Cellurale, M., Fatica, F., Daniele, A., et al.
(2013). Potential mechanisms linking atherosclerosis and increased cardiovas-
cular risk in COPD: focus on sirtuins. Int. J. Mol. Sci. 14, 12696–12713. doi:
10.3390/ijms140612696
Corbi, G., Conti, V., Scapagnini, G., Filippelli, A., and Ferrara, N. (2012a). Role
of sirtuins, calorie restriction and physical activity in aging. Front. Biosci. (Elite
Ed). 4, 768–778. doi: 10.2741/E417
Corbi, G., Conti, V., Russomanno, G., Rengo, G., Vitulli, P., Ciccarelli, A. L.,
et al. (2012b). Is physical activity able to modify oxidative damage in car-
diovascular aging? Oxid. Med. Cell. Longev. 2012:728547. doi: 10.1155/2012/
728547
Dai, D. F., Santana, L. F., Vermulst, M., Tomazela, D. M., Emond, M. J.,
MacCoss, M. J., et al. (2009). Overexpression of catalase targeted to mito-
chondria attenuates murine cardiac aging. Circulation 119, 2789–2797. doi:
10.1161/CIRCULATIONAHA.108.822403
Das, S., Fraga, C. G., and Das, D. K. (2006). Cardioprotective effect of resver-
atrol via HO-1 expression involves p38 map kinase and PI-3-kinase signal-
ing, but does not involve NFkappaB. Free Radic. Res. 40, 1066–1075. doi:
10.1080/10715760600833085
Davies, K. J. (1995). Oxidative stress: the paradox of aerobic life. Biochem. Soc.
Symp. 61, 1–31.
Deibert, D. C., and DeFronzo, R. A. (1980). Epinephrine-induced insulin resistance
in man. J. Clin. Invest. 65, 717–721. doi: 10.1172/JCI109718
Di Lisa, F., Kaludercic, N., and Paolocci, N. (2011). β2-Adrenoceptors, NADPH
oxidase, ROS and p38 MAPK: another ’radical’ road to heart failure? Br. J.
Pharmacol. 162, 1009–1011. doi: 10.1111/j.1476-5381.2010.01130.x
Dioum, E. M., Chen, R., Alexander, M. S., Zhang, Q., Hogg, R. T., Gerard,
R. D., et al. (2009). Regulation of hypoxia-inducible factor 2alpha signaling
by the stress-responsive deacetylase sirtuin 1. Science 324, 1289–1293. doi:
10.1126/science.1169956
Dolinsky, V. W., Chan, A. Y., Robillard Frayne, I., Light, P. E., Des Rosiers,
C., and Dyck, J. R. (2009). Resveratrol prevents the prohypertrophic
effects of oxidative stress on LKB1. Circulation 119, 1643–1652. doi:
10.1161/CIRCULATIONAHA.108.787440
Drake, M. T., Violin, J. D., Whalen, E. J., Wisler, J. W., Shenoy, S. K., and Lefkowitz,
R. J. (2008). b-arrestin-biased agonism at the b2-adrenergic receptor. J. Biol.
Chem. 283, 5669–5676. doi: 10.1074/jbc.M708118200
Dröge, W. (2002). Free radicals in the physiological control of cell function. Physiol.
Rev. 82, 47–95. doi: 10.1152/physrev.00018.2001
Du, J., Zhou, Y., Su, X., Yu, J. J., Khan, S., Jiang, H., et al. (2011). SIRT5 is a NAD-
dependent protein lysine demalonylase and desuccinylase. Science 334, 806–809.
doi: 10.1126/science.1207861
Eskildsen-Helmond, Y. E., Bezstarosti, K., Dekkers, D. H., van Heugten, H. A.,
and Lamers, J. M. (1997). Cross-talk between receptor-mediated phospholipase
C-beta and D via protein kinase C as intracellular signal possibly leading to
hypertrophy in serum-free cultured cardiomyocytes. J. Mol. Cell. Cardiol. 29,
2545–2559. doi: 10.1006/jmcc.1997.0491
Evron, T., Daigle, T. L., and Caron, M. G. (2012). GRK2: multiple roles beyond G
protein-coupled receptor desensitization. Trends Pharmacol. Sci. 33, 154–164.
doi: 10.1016/j.tips.2011.12.003
Feldman, D. S., Elton, T. S., Sun, B., Martin, M. M., and Ziolo, M. T. (2008).
Mechanisms of disease: detrimental adrenergic signaling in acute decom-
pensated heart failure. Nat. Clin. Pract. Cardiovasc. Med. 5, 208–218. doi:
10.1038/ncpcardio1127
Femminella, G. D., Rengo, G., Pagano, G., de Lucia, C., Komici, K., Parisi, V.,
et al. (2013). β-adrenergic receptors and G protein-coupled receptor kinase-2
in Alzheimer’s disease: a new paradigm for prognosis and therapy? J. Alzheimers
Dis. 34, 341–347. doi: 10.3233/JAD-121813
Ferguson, S. S., Downey, W. E. 3rd., Colapietro, A. M., Barak, L. S., Ménard,
L., and Caron, M. G. (1996). Role of beta-arrestin in mediating agonist-
promoted G protein-coupled receptor internalization. Science 271, 363–366.
doi: 10.1126/science.271.5247.363
Ferrara, N., Abete, P., Corbi, G., Paolisso, G., Longobardi, G., Calabrese, C., et al.
(2005). Insulin-induced changes in beta-adrenergic response: an experimental
study in the isolated rat papillary muscle. Am. J. Hypertens. 18, 348–353. doi:
10.1016/j.amjhyper.2004.10.006
Ferrara, N., Corbi, G., Bosimini, E., Cobelli, F., Furgi, G., Giannuzzi, P., et al. (2006).
Cardiac rehabilitation in the elderly: patient selection and outcomes. Am. J.
Geriatr. Cardiol. 15, 22–27. doi: 10.1111/j.1076-7460.2006.05289.x
Ferrara, N., Davia, K., Abete, P., Rengo, F., and Harding, S. E. (1997). Alterations
in beta-adrenoceptor mechanisms in the aging heart. Relationship with heart
failure. Aging (Milano). 9, 391–403.
Ferrara, N., Rinaldi, B., Corbi, G., Conti, V., Stiuso, P., Boccuti, S., et al. (2008).
Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res. 11,
139–150. doi: 10.1089/rej.2007.0576
Finkel, T. (1999). Signal transduction by reactive oxygen species in non-phagocytic
cells. J. Leukoc. Biol. 65, 337–340.
Finkel, T., Deng, C. X., and Mostoslavsky, R. (2009). Recent progress in the biology
and physiology of sirtuins. Nature 460, 587–591. doi: 10.1038/nature08197
Finley, L. W., Carracedo, A., Lee, J., Souza, A., Egia, A., Zhang, J., et al. (2011).
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α
destabilization. Cancer Cell. 19, 416–428. doi: 10.1016/j.ccr.2011.02.014
Ford, E., Voit, R., Liszt, G., Magin, C., Grummt, I., and Guarente, L. (2006).
Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcrip-
tion. Genes Dev. 20, 1075–1080. doi: 10.1101/gad.1399706
Garcia-Guerra, L., Nieto-Vazquez, I., Vila-Bedmar, R., Jurado-Pueyo, M., Zalba,
G., Díez, J., et al. (2010). G protein-coupled receptor kinase 2 plays a relevant
role in insulin resistance and obesity. Diabetes 59, 2407–2417. doi: 10.2337/
db10-0771
Garcia Soriano, F., Viràg, L., and Szabo, C. (2001). Diabetic endothelial dys-
function: role of reactive oxygen and nitrogen species production and
poly(ADP-ribose) polymerase activation. J. Mol. Med. 79, 437–448. doi:
10.1007/s001090100236
Gerhart-Hines, Z., Dominy, J. E. Jr., Blättler, S. M., Jedrychowski, M. P., Banks, A.
S., Lim, J. H., et al. (2011). The cAMP/PKA pathway rapidly activates SIRT1 to
promote fatty acid oxidation independently of changes in NAD(+). Mol. Cell.
44, 851–863. doi: 10.1016/j.molcel.2011.12.005
Gerhart-Hines, Z., Rodgers, J. T., Bare, O., Lerin, C., Kim, S. H., Mostoslavsky,
R., et al. (2007). Metabolic control of muscle mitochondrial function and
fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 26, 1913–1923. doi:
10.1038/sj.emboj.7601633
Giordano, F. J. (2005). Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin.
Invest. 115, 500–508. doi: 10.1172/JCI200524408
Gong, K., Li, Z., Xu, M., Du, J., Lv, Z., and Zhang, Y. (2008). A novel protein kinase
A-independent, b-arrestin-1-dependent signaling pathway for p38 mitogen-
activated protein kinase activation by b2-adrenergic receptors. J. Biol. Chem.
283, 29028–29036. doi: 10.1074/jbc.M801313200
Griendling, K. K., and FitzGerald, G. A. (2003). Oxidative stress and cardiovascular
injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation.
108, 1912–1916. doi: 10.1161/01.CIR.0000093660.86242.BB
Griendling, K. K., Sorescu, D., and Ushio-Fukai, M. (2000). NAD(P)H oxi-
dase: role in cardiovascular biology and disease. Circ Res. 86, 494–501. doi:
10.1161/01.RES.86.5.494
Gros, R., Benovic, J. L., Tan, C. M., and Feldman, R. D. (1997). G-protein-
coupled receptor kinase activity is increased in hypertension. J. Clin. Invest. 99,
2087–2093. doi: 10.1172/JCI119381
Grubisha, O., Smith, B. C., and Denu, J. M. (2005). Small molecule regulation
of Sir2 protein deacetylases. FEBS J. 272, 4607–4616. doi: 10.1111/j.1742-
4658.2005.04862.x
Guarente, L. (2011). Franklin H. Epstein Lecture: sirtuins, aging, and medicine. N.
Engl. J. Med. 364, 2235–2244. doi: 10.1056/NEJMra1100831
Hafner, A. V., Dai, J., Gomes, A. P., Xiao, C. Y., Palmeira, C. M., Rosenzweig, A.,
et al., (2010). Regulation of the mPTP by SIRT3-mediated deacetylation of
CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany
NY). 2, 914–923. doi: 10.3410/f.7816956.8154054
Frontiers in Physiology | Clinical and Translational Physiology November 2013 | Volume 4 | Article 324 | 10
Corbi et al. Sirtuins, oxidative stress and beta-adrenergic system
Haigis, M. C., and Sinclair, D. A. (2010). Mammalian sirtuins: biological insights
and disease relevance. Annu. Rev. Pathol. 5, 253–295. doi: 10.1146/annurev.
pathol.4.110807.092250
Hariharan, N., Maejima, Y., Nakae, J., Paik, J., Depinho, R. A., and Sadoshima,
J. (2010). Deacetylation of FoxO by Sirt1 plays an essential role in mediating
starvation-induced autophagy in cardiac myocytes. Circ. Res. 107, 1470–1482.
doi: 10.1161/CIRCRESAHA.110.227371
Hirotani, S., Otsu, K., Nishida, K., Higuchi, Y., Morita, T., Nakayama, H., et al.
(2002). Involvement of nuclear factor-kappaB and apoptosis signal-regulating
kinase 1 in G-protein-coupled receptor agonistinduced cardiomyocyte hyper-
trophy. Circulation 105, 509–515. doi: 10.1161/hc0402.102863
Hisahara, S., Chiba, S., Matsumoto, H., Tanno, M., Yagi, H., Shimohama, S.,
et al. (2008). Histone deacetylase SIRT1 modulates neuronal differentiation by
its nuclear translocation. Proc. Natl. Acad. Sci. U.S.A. 105, 15599–15604. doi:
10.1073/pnas.0800612105
Ho, Y. S., Magnenat, J. L., Gargano, M., and Cao, J. (1998). The nature of antiox-
idant defense mechanisms: a lesson from transgenic studies. Environ. Health
Perspect. 106, 1219–1228.
Hsu, T. C., Young, M. R., Cmarik, J., and Colburn, N. H. (2000). Activator
protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent tran-
scriptional events in carcinogenesis. Free Radic. Biol. Med. 28, 1338–1348. doi:
10.1016/S0891-5849(00)00220-3
Hua, Y., Zhang, Y., Ceylan-Isik, A.F., Wold, L. E., Nunn, J. M., and Ren, J. (2011).
Chronic Akt activation accentuates aging-induced cardiac hypertrophy and
myocardial contractile dysfunction: role of autophagy. Basic Res. Cardiol. 106,
1173–1191. doi: 10.1007/s00395-011-0222-8
Ide, T., Tsutsui, H., Kinugawa, S., Utsumi, H., Kang, D., Hattori, N., et al.
(1999). Mitochondrial electron transport complex I is a potential source of
oxygen free radicals in the failing myocardium. Circ. Res. 85, 357–363. doi:
10.1161/01.RES.85.4.357
Kahsai, A. W., Zhu, S., and Fenteany, G. (2010). G protein-coupled receptor kinase
2 activates radixin, regulating membrane protrusion and motility in epithe-
lial cells. Biochim. Biophys. Acta. 1803, 300–310. doi: 10.1016/j.bbamcr.2009.
11.002
Kawano, S. (1998). Dual mechanisms of Mg2+ block of ryanodine receptor Ca2+
release channel from cardiac sarcoplasmic reticulum. Receptors Channels 5,
405–416.
Klima, M., Burns, T. R., and Chopra, A. (1990). Myocardial fibrosis in the elderly.
Arch. Pathol. Lab. Med. 114, 938–942.
Knight, J. A. (2000). The biochemistry of aging. Adv. Clin. Chem. 35, 1–62. doi:
10.1016/S0065-2423(01)35014-X
Kohen, R., and Nyska, A. (2002). Oxidation of biological systems: oxidative stress
phenomena, antioxidants, redox reactions, and methods for their quantifica-
tion. Toxicol. Pathol. 30, 620–650. doi: 10.1080/01926230290166724
Kohno, M., Yasunari, K., Murakawa, K., Yokokawa, K., Horio, T., Fukui, T., et al.
(1990). Plasma immunoreactive endothelin in essential hypertension. Am. J.
Med. 88, 614–618. doi: 10.1016/0002-9343(90)90527-K
Koss, K. L., and Grubbs, R. D. (1994). Elevated extracellular Mg2+ increases
Mg2+ buffering through a Ca-dependent mechanism in cardiomyocytes. Am.
J. Physiol. 267, C633–C641.
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F.,
et al. (2006). Resveratrol improves mitochondrial function and protects against
metabolic disease by activating SIRT1 and PGC-1a. Cell 127, 1109–1122. doi:
10.1016/j.cell.2006.11.013
Lee, I. H., Cao, L., Mostoslavsky, R., Lombard, D. B., Liu, J., Bruns, N. E.,
et al. (2008). A role for the NAD-dependent deacetylase Sirt1 in the reg-
ulation of autophagy. Proc. Natl. Acad. Sci. U.S.A. 105, 3374–3379. doi:
10.1073/pnas.0712145105
Li, L., Zhang, H. N., Chen, H. Z., Gao, P., Zhu, L. H., Li, H. L., et al. (2011). SIRT1
acts as a modulator of neointima formation following vascular injury in mice.
Circ. Res. 108, 1180–1189. doi: 10.1161/CIRCRESAHA.110.237875
Li, Y., Huang, T. T., Carlson, E. J., Melov, S., Ursell, P. C., Olson, J. L., et al.
(1995). Dilated cardiomyopathy and neonatal lethality in mutant mice lack-
ing manganese superoxide dismutase. Nat. Genet. 11, 376–381. doi: 10.1038/
ng1295-376
Loch, T., Vakhrusheva, O., Piotrowska, I., Ziolkowski, W., Ebelt, H., Braun, T., et al.
(2009). Different extent of cardiac malfunction and resistance to oxidative stress
in heterozygous and homozygousmanganese-dependent superoxide dismutase-
mutant mice. Cardiovasc. Res. 82, 448–457. doi: 10.1093/cvr/cvp092
Lombard, D. B., Alt, F. W., Cheng, H. L., Bunkenborg, J., Streeper, R. S.,
Mostoslavsky, R., et al. (2007). Mammalian Sir2 homolog SIRT3 regulates
global mitochondrial lysine acetylation. Mol. Cell. Biol. 27, 8807–8814. doi:
10.1128/MCB.01636-07
Lombardi, M. S., Kavelaars, A., Penela, P., Scholtens, E. J., Roccio, M., Schmidt, R.
E., et al. (2002). Oxidative stress decreases G protein-coupled receptor kinase
2 in lymphocytes via a calpain-dependent mechanism. Mol. Pharmacol. 62,
379–388. doi: 10.1124/mol.62.2.379
Lu, Z., Bourdi, M., Li, J. H., Aponte, A. M., Chen, Y., Lombard, D. B., et al.
(2011). SIRT3-dependent deacetylation exacerbates acetaminophen hepatotox-
icity. EMBO Rep. 12, 840–846. doi: 10.1038/embor.2011.121
Machida, Y., Kubota, T., Kawamura, N., Funakoshi, H., Ide, T., Utsumi, H., et al.
(2003). Overexpression of tumor necrosis factor-alpha increases production of
hydroxyl radical in murine myocardium. Am. J. Physiol. Heart Circ. Physiol. 284,
H449–H455.
Mann, D. L., and Bristow, M. R. (2005). Mechanisms and models in heart fail-
ure: the biomechanical model and beyond. Circulation 111, 2837–2849. doi:
10.1161/CIRCULATIONAHA.104.500546
Marciano, C., Galderisi, M., Gargiulo, P., Acampa, W., D’Amore, C., Esposito, R.,
et al. (2012). Effects of type 2 diabetes mellitus on coronary microvascular func-
tion and myocardial perfusion in patients without obstructive coronary artery
disease. Eur. J. Nucl. Med. Mol. Imaging 39, 1199–1206. doi: 10.1007/s00259-
012-2117-9
Martin, J. L., Mestril, R., Hilal-Dandan, R., Brunton, L. L., and Dillmann, W. H.
(1997). Small heat shock proteins and protection against ischemic injury in
cardiac myocytes. Circulation 96, 4343–4348. doi: 10.1161/01.CIR.96.12.4343
McAlees, J. W., and Sanders, V. M. (2009). Hematopoietic protein tyrosine phos-
phatase mediates b2-adrenergic receptor-induced regulation of p38 mitogen-
activated protein kinase in B lymphocytes. Mol. Cell. Biol. 29, 675–686. doi:
10.1128/MCB.01466-08
Merksamer, P. I., Liu, Y., He, W., Hirschey, M. D., Chen, D., and Verdin,
E. (2013). The sirtuins, oxidative stress and aging: an emerging link.
Aging (Albany NY) 5, 144–150. Available online at: http://www.impactaging.
com/papers/v5/n3/full/100544.html
Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C., and Horikawa, I. (2005).
Evolutionarily conserved and nonconserved cellular localizations and functions
of human SIRT proteins. Mol. Biol. Cell. 16, 4623–4635. doi: 10.1091/mbc.E05-
01-0033
Miyazaki, R., Ichiki, T., Hashimoto, T., Inanaga, K., Imayama, I., Sadoshima, J., et al.
(2008). SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor
expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 28,
1263–1269. doi: 10.1161/ATVBAHA.108.166991
Molenaar, P., Savarimuthu, S. M., Sarsero, D., Chen, L., Semmler, A. B., Carle, A.,
et al. (2007). (-)-Adrenaline elicits positive inotropic, lusitropic, and biochem-
ical effects through beta2 -adrenoceptors in human atrial myocardium from
nonfailing and failing hearts, consistent with Gs coupling but not with Gi cou-
pling.Naunyn Schmiedebergs Arch. Pharmacol. 375, 11–28. doi: 10.1007/s00210-
007-0138-x
Nadtochiy, S. M., Yao, H., McBurney, M. W., Gu, W., Guarente, L., Rahman, I.,
et al. (2011). SIRT1-mediated acute cardioprotection. Am. J. Physiol. Heart Circ.
Physiol. 301, H1506–1512. doi: 10.1152/ajpheart.00587.2011
Naga Prasad, S. V., Barak, L. S., Rapacciuolo, A., Caron, M. G., and
Rockman, H. A. (2001). Agonist-dependent recruitment of phosphoinosi-
tide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role
in receptor sequestration. J. Biol. Chem. 276, 18953–18959. doi: 10.1074/jbc.
M102376200
Naga Prasad, S. V., Laporte, S. A., Chamberlain, D., Caron, M. G., Barak, L., and
Rockman, H. A. (2002). Phosphoinositide 3-kinase regulates beta2-adrenergic
receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin com-
plex. J. Cell. Biol. 158, 563–575. doi: 10.1083/jcb.200202113
Nakamura, K., Fushimi, K., Kouchi, H., Mihara, K., Miyazaki, M., Ohe, T., et al.
(1998). Inhibitory effects of antioxidants on neonatal rat cardiacmyocyte hyper-
trophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation.
98, 794–799. doi: 10.1161/01.CIR.98.8.794
Nasrin, N., Kaushik, V. K., Fortier, E., Wall, D., Pearson, K. J., de Cabo, R., et al.
(2009). JNK1 phosphorylates SIRT1 and promotes its enzymatic activity. PLoS
ONE 4:e8414. doi: 10.1371/journal.pone.0008414
Navarro-Arévalo, A., Cañavate, C., and Sánchez-del-Pino, M. J. (1999). Myocardial
and skeletal muscle aging and changes in oxidative stress in relationship to
www.frontiersin.org November 2013 | Volume 4 | Article 324 | 11
Corbi et al. Sirtuins, oxidative stress and beta-adrenergic system
rigorous exercise training.Mech. Ageing Dev. 108, 207–217. doi: 10.1016/S0047-
6374(99)00013-5
Nishida, M., Maruyama, Y., Tanaka, R., Kontani, K., Nagao, T., and Kurose, H.
(2000). G alpha(i) and G alpha(o) are target proteins of reactive oxygen species.
Nature. 408, 492–495. doi: 10.1038/35044120
Oellerich, M. F., and Potente, M. (2012). FOXOs and sirtuins in vas-
cular growth, maintenance, and aging. Circ. Res. 110, 1238–1251. doi:
10.1161/CIRCRESAHA.111.246488
Opie, L. H., and Lecour, S. (2007). The red wine hypothesis: from concepts to pro-
tective signalling molecules. Eur. Heart J. 28, 1683–1693. doi: 10.1093/eurheartj/
ehm149
Ota, H., Akishita, M., Eto, M., Iijima, K., Kaneki, M., and Ouchi, Y. (2007). Sirt1
modulates premature senescence-like phenotype in human endothelial cells.
J. Mol. Cell. Cardiol. 43, 571–579. doi: 10.1016/j.yjmcc.2007.08.008
Packer, M. (1998). Beta-blockade in heart failure. Basic concepts and clinical
results. Am. J. Hypertens. 11, 23S-37S. doi: 10.1016/S0895-7061(97)00425-1
Paolillo, S., Rengo, G., Pagano, G., Pellegrino, T., Savarese, G., Femminella, G. D.,
et al. (2013). Impact of diabetes on cardiac sympathetic innervation in patients
with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic
study. Diabetes Care. 36, 2395–2401. doi: 10.2337/dc12-2147
Penela, P., Ruiz-Gómez, A., Castaño, J. G.„ and Mayor, F. Jr. (1998). Degradation
of the G protein-coupled receptor kinase 2 by the proteasome pathway. J. Biol.
Chem. 273, 35238–35244. doi: 10.1074/jbc.273.52.35238
Perrino, C., Naga Prasad, S. V., Schroder, J. N., Hata, J. A., Milano, C.,
and Rockman, H. A. (2005). Restoration of beta-adrenergic receptor sig-
naling and contractile function in heart failure by disruption of the
betaARK1/phosphoinositide 3-kinase complex. Circulation. 111, 2579–2587.
doi: 10.1161/CIRCULATIONAHA.104.508796
Pierce, K. L., Premont, R. T., and Lefkowitz, R. J. (2002). Seven-transmembrane
receptors. Nat. Rev. Mol. Cell. Biol. 3, 639–650. doi: 10.1038/nrm908
Pillai, J. B., Isbatan, A., Imai, S., and Gupta, M. P. (2005). Poly(ADP-ribose)
polymerase-1-dependent cardiac myocyte cell death during heart failure is
mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J. Biol.
Chem. 80, 43121–43130. doi: 10.1074/jbc.M506162200
Pitcher, J. A., Freedman, N. J., and Lefkowitz, R. J. (1998a). G protein-
coupled receptor kinases. Annu. Rev. Biochem. 67, 653–692. doi:
10.1146/annurev.biochem.67.1.653
Pitcher, J. A., Hall, R. A., Daaka, Y., Zhang, J., Ferguson, S. S., Hester, S., et al.
(1998b). The G protein-coupled receptor kinase 2 is a microtubule-associated
protein kinase that phosphorylates tubulin. J. Biol. Chem. 273,12316–12324.
doi: 10.1074/jbc.273.20.12316
Porcu, M., and Chiarugi, A. (2005). The emerging therapeutic potential of sirtuin-
interacting drugs: from cell death to lifespan extension. Trends Pharmacol. Sci.
26, 94–103. doi: 10.1016/j.tips.2004.12.009
Post, S. R., Hammond, H. K., and Insel, P. A. (1999). Beta-adrenergic receptors and
receptor signaling in heart failure. Annu. Rev. Pharmacol. Toxicol. 39, 343–601.
doi: 10.1146/annurev.pharmtox.39.1.343
Rane, S., He, M., Sayed, D., Yan, L., Vatner, D., and Abdellatif, M. (2010). An
antagonism between the AKT and beta-adrenergic signaling pathways mediated
through their reciprocal effects onmiR-199a-5p.Cell Signal. 22, 1054–1062. doi:
10.1016/j.cellsig.2010.02.008
Remacle, J., Raes, M., Toussaint, O., Renard, P., and Rao, G. (1995). Low levels of
reactive oxygen species as modulators of cell function.Mutat. Res. 316, 103–122.
doi: 10.1016/0921-8734(95)90004-7
Rengo, G., Cannavo, A., Liccardo, D., Zincarelli, C., de Lucia, C., Pagano, G., et al.
(2013a). Vascular endothelial growth factor blockade prevents the beneficial
effects of β-blocker therapy on cardiac function, angiogenesis and remodeling in
heart failure. Circ. Heart Fail. doi: 10.1161/CIRCHEARTFAILURE.113.000329.
[Epub ahead of print].
Rengo, G., Pagano, G., Squizzato, A., Moja, L., Femminella, G. D., de Lucia,
C., et al. (2013b). Oral anticoagulation therapy in heart failure patients in
sinus rhythm: a systematic review and meta-analysis. PLoS ONE. 8:e52952. doi:
10.1371/journal.pone.0052952
Rengo, G., Galasso, G., Femminella, G. D., Parisi, V., Zincarelli, C., Pagano, G., et al.
(2013c). Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2)
after exercise training predicts survival in patients with heart failure. Eur. J. Prev.
Cardiol. doi: 10.1177/2047487313491656. [Epub ahead of print].
Rengo, G., Leosco, D., Zincarelli, C., Marchese, M., Corbi, G., Liccardo, D.,
et al. (2010). Adrenal GRK2 lowering is an underlying mechanism for the
beneficial sympathetic effects of exercise training in heart failure. Am. J.
Physiol. Heart Circ. Physiol. 298, H2032–H2038. doi: 10.1152/ajpheart.00702.
2009
Rengo, G., Perrone-Filardi, P., Femminella, G. D., Liccardo, D., Zincarelli, C., de
Lucia, C., et al. (2012a). Targeting the β-adrenergic receptor system through G-
protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic
evaluation in heart failure: from bench to bedside. Circ. Heart Fail. 5, 385–391.
doi: 10.1161/CIRCHEARTFAILURE.112.966895
Rengo, G., Zincarelli, C., Femminella, G. D., Liccardo, D., Pagano, G., de Lucia,
C., et al. (2012b). Myocardial β(2) -adrenoceptor gene delivery promotes coor-
dinated cardiac adaptive remodelling and angiogenesis in heart failure. Br. J.
Pharmacol. 166, 2348–2361. doi: 10.1111/j.1476-5381.2012.01954.x
Rengo, G., Lymperopoulos, A., Zincarelli, C., Femminella, G., Liccardo, D.,
Pagano, G., et al. (2012c). Blockade of β-adrenoceptors restores the GRK2-
mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart
failure. Br. J. Pharmacol. 166, 2430–2440. doi: 10.1111/j.1476-5381.2012.
01972.x
Rinaldi, B., Corbi, G., Boccuti, S., Filippelli, W., Rengo, G., Leosco, D., et al.
(2006). Exercise training affects age-induced changes in SOD and heat
shock protein expression in rat heart. Exp. Gerontol. 41, 764–770. doi:
10.1016/j.exger.2006.05.008
Rockman, H. A., Koch, W. J., and Lefkowitz, R. J. (2002). Seven-transmembrane-
spanning receptors and heart function. Nature. 415, 206–212. doi:
10.1038/415206a
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., and Puigserver,
P. (2005). Nutrient control of glucose homeostasis through a complex of PGC-
1alpha and SIRT1. Nature 434, 113–118. doi: 10.1038/nature03354
Sabri, A., Hughie, H. H., and Lucchesi, P. A. (2003). Regulation of hypertrophic and
apoptotic signaling pathways by reactive oxygen species in cardiac myocytes.
Antioxid. Redox Signal. 5, 731–740. doi: 10.1089/152308603770380034
Salazar, N. C., Vallejos, X., Siryk, A., Rengo, G., Cannavo, A., Liccardo, D., et al.
(2013). GRK2 blockade with betaARKct is essential for cardiac beta2-adrenergic
receptor signaling towards increased contractility. Cell. Commun. Signal. 11,
2348–2361. doi: 10.1186/1478-811X-11-64
Salcedo, A., Mayor, F. Jr, and Penela, P. (2006). Mdm2 is involved in the ubiqui-
tination and degradation of G-protein-coupled receptor kinase 2. EMBO J. 25,
4752–4762. doi: 10.1038/sj.emboj.7601351
Santulli, G., Campanile, A., Spinelli, L., Assante di Panzillo, E., Ciccarelli,
M., Trimarco, B., et al. (2011). G protein-coupled receptor kinase 2 in
patients with acute myocardial infarction. Am. J. Cardiol. 107, 1125–1130. doi:
10.1016/j.amjcard.2010.12.006
Santulli, G., Trimarco, B., and Iaccarino, G. (2013). G-protein-coupled receptor
kinase 2 and hypertension: molecular insights and pathophysiological mecha-
nisms. High Blood Press. Cardiovasc. Prev. 20, 5–12. doi: 10.1007/s40292-013-
0001-8
Sawyer, D. B., Siwik, D. A., Xiao, L., Pimentel, D. R., Singh, K., and Colucci, W. S.
(2002). Role of oxidative stress in myocardial hypertrophy and failure. J. Mol.
Cell. Cardiol. 34, 379–388. doi: 10.1006/jmcc.2002.1526
Schieven, G. L., Kirihara, J. M., Myers, D. E., Ledbetter, J. A., and Uckun, F. M.
(1993). Reactive oxygen intermediates activate NF-kappa B in a tyrosine kinase-
dependent mechanism and in combination with vanadate activate the p56lck
and p59fyn tyrosine kinases in human lymphocytes. Blood. 82, 1212–1220.
Schlicker, C., Gertz, M., Papatheodorou, P., Kachholz, B., Becker, C. F., and
Steegborn, C. (2008). Substrates and regulation mechanisms for the human
mitochondrial sirtuins Sirt3 and Sirt5. J. Mol. Biol. 382, 790–801. doi:
10.1016/j.jmb.2008.07.048
Schreck, R., Rieber, P., and Baeuerle, P. A. (1991). Reactive oxygen intermedi-
ates as apparently widely used messengers in the activation of the NF-kappa
B transcription factor and HIV-1. EMBO J. 10, 2247–2258.
Schriner, S. E., Linford, N. J., Martin, G.M., Treuting, P., Ogburn, C. E., Emond,M.,
et al. (2005). Extension ofmurine life span by overexpression of catalase targeted
to mitochondria. Science. 308, 1909–1911. doi: 10.1126/science.1106653
Schug, T. T., and Li, X. (2010). Surprising sirtuin crosstalk in the heart.
Aging (Albany NY). 2, 129–132. Available online at: http://www.impactaging.
com/papers/v2/n3/full/100128.html
Scortegagna,M., Ding, K., Oktay, Y., Gaur, A., Thurmond, F., Yan, L. J., et al. (2003).
Multiple organ pathology, metabolic abnormalities and impaired homeosta-
sis of reactive oxygen species in Epas1–/– mice. Nat. Genet. 35, 331–340. doi:
10.1038/ng1266
Frontiers in Physiology | Clinical and Translational Physiology November 2013 | Volume 4 | Article 324 | 12
Corbi et al. Sirtuins, oxidative stress and beta-adrenergic system
Seddon, M., Looi, Y. H., and Shah, A. M. (2007). Oxidative stress and redox
signalling in cardiac hypertrophy and heart failure. Heart. 93, 903–907. doi:
10.1136/hrt.2005.068270
Sethi, R., Saini, H. K., Guo, X., Wang, X., Elimban, V., and Dhalla, N. S. (2007).
Dependence of changes in beta-adrenoceptor signal transduction on type and
stage of cardiac hypertrophy. J. Appl. Physiol. 102, 978–984. doi: 10.1152/jap-
plphysiol.00921.2006
Shinmura, K., Tamaki, K., Sano, M., Nakashima-Kamimura, N., Wolf, A. M.,
Amo, T., et al. (2011). Caloric restriction primes mitochondria for ischemic
stress by deacetylating specific mitochondrial proteins of the electron trans-
port chain. Circ. Res. 109, 396–406. 92. doi: 10.1161/CIRCRESAHA.111.
243097
Singal, P. K., Petkau, A., Gerrard, J. M., Hrushovetz, S., and Foerster, J. (1988).
Free radicals in health and disease. Mol. Cell. Biochem. 84, 121–122. doi:
10.1007/BF00421045
Sorescu, D., and Griendling, K. K. (2002). Reactive oxygen species, mitochondria,
and NAD(P)H oxidases in the development and progression of heart failure.
Congest Heart Fail. 8, 132–140. doi: 10.1111/j.1527-5299.2002.00717.x
Stein, S., and Matter, C. M. (2011). Protective roles of SIRT1 in atherosclerosis. Cell
Cycle. 10, 640–647. doi: 10.4161/cc.10.4.14863
Stiles, G. L., Caron, M. G., and Lefkowitz, R. J. (1984). Beta-adrenergic recep-
tors: biochemical mechanisms of physiological regulation. Physiol. Rev. 64,
661–743.
Suematsu, N., Tsutsui, H., Wen, J., Kang, D., Ikeuchi, M., Ide, T., et al. (2003).
Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial
DNA damage and dysfunction in cardiacmyocytes.Circulation. 107, 1418–1423.
doi: 10.1161/01.CIR.0000055318.09997.1F
Sulaiman, M., Matta, M. J., Sunderesan, N. R., Gupta, M. P., Periasamy, M., and
Gupta, M. (2010). Resveratrol, an activator of SIRT1, upregulates sarcoplasmic
calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am.
J. Physiol. Heart Circ. Physiol. 29, H833–H843. doi: 10.1152/ajpheart.00418.2009
Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X., et al. (2007). SIRT1 improves
insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell
Metab. 6, 307–319. doi: 10.1016/j.cmet.2007.08.014
Sunagawa, K. (2008). SIRT1, a longevity gene, downregulates angiotensin II type 1
receptor expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc.
Biol. 28, 1263–1269. doi: 10.1161/ATVBAHA.108.166991
Sundaresan, N. R., Gupta, M., Kim, G., Rajamohan, S. B., Isbatan, A., and Gupta,
M. P. (2009). Sirt3 blocks the cardiac hypertrophic response by augmenting
Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 119,
2758–2771. doi: 10.1172/JCI39162
Sundaresan, N. R., Samant, S. A., Pillai, V. B., Rajamohan, S. B., and Gupta, M. P.
(2008). SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects
cells from stress-mediated cell death by deacetylation of Ku70. Mol. Cell. Biol.
28, 6384–6401. doi: 10.1128/MCB.00426-08
Takeda, S., Kadowaki, S., Haga, T., Takaesu, H., and Mitaku, S. (2002).
Identification of G protein-coupled receptor genes from the human genome
sequence. FEBS Lett. 520, 97–101. doi: 10.1016/S0014-5793(02)02775-8
Tang, Y., Xu, J., Qu, W., Peng, X., Xin, P., Yang, X., et al. (2012). Resveratrol
reduces vascular cell senescence through attenuation of oxidative stress
by SIRT1/NADPH oxidase-dependent mechanisms. J. Nutr. Biochem. 23,
1410–1416. doi: 10.1016/j.jnutbio.2011.08.008
Tanno, M., Kuno, A., Horio, Y., and Miura, T. (2012). Emerging beneficial roles of
sirtuins in heart failure. Basic Res. Cardiol 107, 273. doi: 10.1007/s00395-012-
0273-5
Tanno, M., Kuno, A., Yano, T., Miura, T., Hisahara, S., Ishikawa, S., et al. (2010).
Induction of manganese superoxide dismutase by nuclear translocation and
activation of SIRT1 promotes cell survival in chronic heart failure. J. Biol. Chem.
285, 8375–8382. doi: 10.1074/jbc.M109.090266
Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K., and Horio, Y. (2007).
Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase
SIRT1. J. Biol. Chem. 282, 6823–6832. doi: 10.1074/jbc.M609554200
Tavares, M., Rezlan, E., Vostroknoutova, I., Khouadja, H., and Mebazaa, A. (2008).
New pharmacologic therapies for acute heart failure. Crit. Care Med. 36, S112–
120. doi: 10.1097/01.CCM.0000296810.74724.8D
Thandapilly, S. J., Louis, X. L., Yang, T., Stringer, D. M., Yu, L., Zhang, S., et al.
(2011). Resveratrol prevents norepinephrine induced hypertrophy in adult rat
cardiomyocytes, by activating NO-AMPK pathway. Eur. J. Pharmacol. 668,
217–224. doi: 10.1016/j.ejphar.2011.06.042
Thandapilly, S. J., Wojciechowski, P., Behbahani, J., Louis, X. L., Yu, L.,
Juric, D., et al. (2010). Resveratrol prevents the development of patholog-
ical cardiac hypertrophy and contractile dysfunction in the SHR without
lowering blood pressure. Am. J. Hypertens. 23, 192–196. doi: 10.1038/ajh.
2009.228
Thannickal, V. J., and Fanburg, B. L. (2000). Reactive oxygen species in cell
signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 279, L1005–L1028.
Tilley, D. G., Kim, I. M., Patel, P. A., Violin, J. D., and Rockman, H. A. (2009).
b-Arrestin mediates b1-adrenergic receptor-epidermal growth factor receptor
interaction and downstream signaling. J. Biol. Chem. 284, 20375–20386. doi:
10.1074/jbc.M109.005793
Turpaev, K. T. (2002). Reactive oxygen species and regulation of gene expression.
Biochemistry Mosc. 67, 281–292. doi: 10.1023/A:1014819832003
Ungerer, M., Parruti, G., Böhm, M., Puzicha, M., DeBlasi, A., Erdmann, E., et al.
(1994). Expression of beta-arrestins and beta-adrenergic receptor kinases in the
failing human heart. Circ. Res. 74, 206–213. doi: 10.1161/01.RES.74.2.206
Usui, I., Imamura, T., Babendure, J. L., Satoh, H., Lu, J. C., Hupfeld, C. J., et al.
(2005). G protein-coupled receptor kinase 2 mediates endothelin-1-induced
insulin resistance via the inhibition of both Galphaq/11 and insulin receptor
substrate-1 pathways in 3T3-L1 adipocytes.Mol. Endocrinol. 19, 2760–2768. doi:
10.1210/me.2004-0429
Usui, I., Imamura, T., Satoh, H., Huang, J., Babendure, J. L., Hupfeld, C. J.,
et al. (2004). GRK2 is an endogenous protein inhibitor of the insulin signal-
ing pathway for glucose transport stimulation. EMBO J. 23, 2821–2829. doi:
10.1038/sj.emboj.7600297
Vakhrusheva, O., Smolka, C., Gajawada, P., Kostin, S., Boettger, T., Kubin, T., et al.
(2008). Sirt7 increases stress resistance of cardiomyocytes and prevents apop-
tosis and inflammatory cardiomyopathy in mice. Circ. Res. 102, 703–710. doi:
10.1161/CIRCRESAHA.107.164558
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., and Telser, J.
(2007). Free radicals and antioxidants in normal physiological functions and
human disease. Int. J. Biochem. Cell. Biol. 39, 44–84. doi: 10.1016/j.biocel.2006.
07.001
van der Horst, A., Tertoolen, L. G., de Vries-Smits, L. M., Frye, R. A., Medema,
R. H., and Burgering, B. M. (2004). FOXO4 is acetylated upon peroxide stress
and deacetylated by the longevity protein hSir2(SIRT1). J. Biol. Chem. 279,
28873–28879. doi: 10.1074/jbc.M401138200
Varma, S. D. (1991). Devamanoharan PS hydrogen peroxide in human blood. Free
Radic. Res. Commun. 14, 125–131. doi: 10.3109/10715769109094124
Venkatasubramanian, S., Noh, R. M., Daga, S., Langrish, J. P., Joshi, N. V., Mills,
N. L., et al. (2013). Cardiovascular effects of a novel SIRT1 activator, SRT2104,
in otherwise healthy cigarette smokers. J. Am. Heart. Assoc. 2:e000042. doi:
10.1161/JAHA.113.000042
von Harsdorf, R., Li, P. F., and Dietz, R. (1999). Signaling pathways in reactive oxy-
gen species-induced cardiomyocyte apoptosis. Circulation 99, 2934–2941. doi:
10.1161/01.CIR.99.22.2934
Vroon, A., Lombardi, M. S., Kavelaars, A., and Heijnen, C. J. (2007). Taxol
normalizes the impaired agonist-induced beta2-adrenoceptor internalization
in splenocytes from GRK2+/- mice. Eur. J. Pharmacol. 560, 9–16. doi:
10.1016/j.ejphar.2007.01.007
Wallace, D. C. (2001). Mouse models for mitochondrial disease. Am. J. Med. Genet.
106, 71–93. doi: 10.1002/ajmg.1393
Westerheide, S. D., Anckar, J., Stevens, S.M. Jr, Sistonen, L., and Morimoto, R. I.
(2009). Stress-inducible regulation of heat shock factor 1 by the deacetylase
SIRT1. Science. 323, 1063–1066. doi: 10.1126/science.1165946
Wu, H. M., Chi, K. H., and Lin, W. W. (2002). Proteasome inhibitors stimulate
activator protein-1 pathway via reactive oxygen species production. FEBS Lett.
526, 101–105. doi: 10.1016/S0014-5793(02)03151-4
Xu, Q., Dalic, A., Fang, L., Kiriazis, H., Ritchie, R. H., Sim, K., et al.
(2011). Myocardial oxidative stress contributes to transgenic β2-adrenoceptor
activation-induced cardiomyopathy and heart failure. Br. J. Pharmacol. 162,
1012–1028. doi: 10.1111/j.1476-5381.2010.01043.x
Yatabe, M. S., Yatabe, J., Yoneda, M., Watanabe, T., Otsuki, M., Felder, R. A.,
et al. (2010). Salt sensitivity is associated with insulin resistance, sympa-
thetic overactivity, and decreased suppression of circulating renin activity in
lean patients with essential hypertension. Am. J. Clin. Nutr. 92, 77–82. doi:
10.3945/ajcn.2009.29028
Yen, H. C., Oberley, T. D., Vichitbandha, S., Ho, Y. S., and St Clair, D. K. (1996).
The protective role of manganese superoxide dismutase against adriamycin-
www.frontiersin.org November 2013 | Volume 4 | Article 324 | 13
Corbi et al. Sirtuins, oxidative stress and beta-adrenergic system
induced acute cardiac toxicity in transgenic mice. J. Clin. Invest. 98, 1253–1260.
doi: 10.1172/JCI118909
Yin, F., Wang, Y. Y., Du, J. H., Li, C., Lu, Z. Z., Han, C., et al. (2006). Noncanonical
cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-
6 production in neonatal mouse cardiac fibroblasts. J. Mol. Cell. Cardiol. 40,
384–393. doi: 10.1016/j.yjmcc.2005.12.005
Yoshida, N., Haga, K., and Haga, T. (2003). Identification of sites of phosphory-
lation by G-protein-coupled receptor kinase 2 in beta-tubulin. Eur. J. Biochem.
270, 1154–1163. doi: 10.1046/j.1432-1033.2003.03465.x
Zheng, M., Zhu, W., Han, Q., and Xiao, R. P. (2005). Emerging concepts and ther-
apeutic implications of beta-adrenergic receptor subtype signaling. Pharmacol.
Ther. 108, 257–268. doi: 10.1016/j.pharmthera.2005.04.006
Zhong, L., and Mostoslavsky, R. (2011). Fine tuning our cellular facto-
ries: sirtuins in mitochondrial biology. Cell. Metab. 13, 621–626. doi:
10.1016/j.cmet.2011.05.004
Zweier, J. L., Kuppusamy, P., Williams, R., Rayburn, B. K., Smith, D., Weisfeldt, M.
L., et al. (1989). Measurement and characterization of postischemic free radical
generation in the isolated perfused heart. J. Biol. Chem. 264, 18890–18895.
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 13 August 2013; paper pending published: 11 September 2013; accepted: 18
October 2013; published online: 08 November 2013.
Citation: Corbi G, Conti V, Russomanno G, Longobardi G, Furgi G, Filippelli A and
Ferrara N (2013) Adrenergic signaling and oxidative stress: a role for sirtuins? Front.
Physiol. 4:324. doi: 10.3389/fphys.2013.00324
This article was submitted to Clinical and Translational Physiology, a section of the
journal Frontiers in Physiology.
Copyright © 2013 Corbi, Conti, Russomanno, Longobardi, Furgi, Filippelli and
Ferrara. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Physiology | Clinical and Translational Physiology November 2013 | Volume 4 | Article 324 | 14
